Columns: General -- Sales -- Acquisition -- WAC
| OSHPD ID | Manufacturer Name | Date Reported | Description | Unit Sales Volume (US) | Gross Sales (USD) | Cost Increase Factors | Change Improvement Description |
|---|---|---|---|---|---|---|---|
| Rx0000077 | AbbVie | 04/29/2024 | CREON 12000USP DELAYED-RELEASE 100CAP |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | CREON 12000USP DELAYED-RELEASE 250CAP |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | CREON 24000USP DELAYED-RELEASE 100CAP |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | CREON 24000USP DELAYED-RELEASE 250CAP |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | CREON 3000USP DELAYED-RELEASE 70CAP |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | CREON 36000USP DELAYED-RELEASE 100CAP |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | CREON 36000USP DELAYED-RELEASE 250CAP |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | CREON 6000USP DELAYED-RELEASE 100CAP |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 140 mg Capsules, 120-count |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 140 mg Tablets, 28-count |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 280 mg Tablets, 28-count |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 420 mg Tablets, 28-count |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 70 mg Capsules, 28-count |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA140 mg Capsules, 90-count |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | ORIAHNN CAPSULES 300MG/1MG/0.5MG; 4x14 |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | ORILISSA 150MG TABS, 4X7 PACK |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | ORILISSA 200MG TABS, 4X14 PACK |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | RINVOQ 15MG 30 DAY BOTTLE |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | SKYRIZI INJ 150MG/ML SINGLE-DOSE PEN |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | SKYRIZI INJ 150MG/ML SINGLE-DOSE PREFILLED SYRINGE |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 100MG BOTTLE 180 TABLETS |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 100MG BOTTLE 180 TABLETS |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 100MG BOTTLE, 120 TABLETS |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 100MG BOTTLE, 120 TABLETS |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 100MG UNIT DOSE, 1 TABLET |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 100MG UNIT DOSE, 1 TABLET |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 10MG UNIT DOSE, 2 TABLETS |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 10MG UNIT DOSE, 2 TABLETS |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 10MG WALLET, 2 TABLETS X 7 |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 10MG WALLET, 2 TABLETS X 7 |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 50MG UNIT DOSE, 1 TABLET |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 50MG UNIT DOSE, 1 TABLET |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 50MG WALLET, 1 TABLET X 7 |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 50MG WALLET, 1 TABLET X 7 |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA START PACK, 4X7 DAY WALLET |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA START PACK, 4X7 DAY WALLET |
|
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. | NA | |
| Rx0000021 | Acorda Therapeutics, Inc. | 04/05/2024 | Ampyra Oral Tablet Extended Release 12 Hour 10 MG Package Size 60 - 1 Bottle |
|
|||
| Rx0000021 | Acorda Therapeutics, Inc. | 04/05/2024 | Inbrija Inhalation Capsule 42 MG Package Size 60 - 1 Box |
|
|||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | OPSUMIT® (macitentan)Strength:10 mg Package Size:15 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | OPSUMIT® (macitentan)Strength:10 mg Package Size:30 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1800mcg Package Size:1 Form:Vial |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 100mg - 2 Capsules per blister pack - 30 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 1mg - 3 Capsules per blister pack - 45 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 1mg - 6 Capsules per blister pack - 90 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 1mg-3 & 10mg-1 Capsules per blister pack - 45 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg - 1 Capsule per blister pack - 15 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg - 2 Capsules per blister pack - 30 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg - 4 Capsules per blister pack - 60 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg-1 & 100mg - 1 Capsules per blister pack - 30 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg-2 & 100mg - 2 Capsules per blister pack - 60 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg-3 & 100mg - 1 Capsules per blister pack - 60 capsules per blister pack |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Sachet - 300mg - 15 Sachet |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Sachet - 300mg - 30 Sachet |
|
Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives. | |
| Rx0000400 | AkaRx, Inc., a Sobi Company | 04/12/2024 | DOPTELET, 1 BLISTER PACK in 1 CARTON > 10 TABLET, EQ 20MG BASE |
|
AkaRx Inc. pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing. | This WAC increase is not necessitated by a change or improvement in the prescription drug. | |
| Rx0000400 | AkaRx, Inc., a Sobi Company | 04/12/2024 | DOPTELET, 1 BLISTER PACK in 1 CARTON > 15 TABLET, EQ 20MG BASE |
|
AkaRx Inc. pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing. | This WAC increase is not necessitated by a change or improvement in the prescription drug. | |
| Rx0000400 | AkaRx, Inc., a Sobi Company | 04/12/2024 | DOPTELET, 2 BLISTER PACK in 1 CARTON / 15 TABLET, FILM COATED in 1 BLISTER PACK, EQ 20MG BASE |
|
AkaRx Inc. pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing. | This WAC increase is not necessitated by a change or improvement in the prescription drug. | |
| Rx0000417 | Akebia Therapeutics, Inc. | 03/31/2024 | Auryxia (Ferric Citrate) 210 mg, 200 Tablets per Bottle |
|
Akebia Therapeutics pricing decisions factor in multiple variables and considerations including but not limited to: competitive and market dynamics, increasing supply chain and overhead costs, distribution and wholesaler fees, and research and development costs. | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Alcaine Ophthalmic Solution 0.5 % 15ml per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | BSS Plus Intraocular Solution 500ml per package, Flex cont |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | BSS Plus Intraocular Solution 500ml per package, Flex cont |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | BSS Plus Intraocular Solution 500ml per package, Glass Cont |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | BSS Plus Intraocular Solution 500ml per package, Glass Cont |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 0.5 % 15ml per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 1 % 5ml per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 2 % 15ml per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 2 % 2ml per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 2 % 5ml per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclomydril Ophthalmic Solution 0.2-1 % 5ml per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Isopto Atropine Ophthalmic Solution 1 % 5ml per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Miostat Intraocular Solution 0.01 % 12 vials per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Mydriacyl Ophthalmic Solution 1 % 15ml per package |
|
The company raised the wholesale acquisition cost of the drug product by the relevant amount in response to inflationary and other economic pressures that increases the costs of raw materials, production, and shipping | ||
| Rx0000272 | Alexion Pharmaceuticals | 04/30/2024 | CAPSULE 10MG 28 COUNT | 6189767 | When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexions pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. | No changes to report, product launched on 05/20/2021 | |
| Rx0000272 | Alexion Pharmaceuticals | 04/30/2024 | CAPSULE 10MG 60 COUNT | 97231288 | When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexions pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. | No changes to report, product launched on 05/20/2021 | |
| Rx0000272 | Alexion Pharmaceuticals | 04/30/2024 | CAPSULE 25MG 28 COUNT | 8520012 | When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexions pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. | No changes to report, product launched on 05/20/2021 | |
| Rx0000272 | Alexion Pharmaceuticals | 04/30/2024 | CAPSULE 25MG 60 COUNT | 111964215 | When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexions pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. | No changes to report, product launched on 05/20/2021 | |
| Rx0000459 | AltaThera Pharmaceuticals LLC | 03/31/2024 | Sotalol hydrochloride - Injection: 10-mL vial containing sotalol hydrochloride 150 mg | 5107 | |||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Alfuzosin HCl Tab ER 24HR 10 MG, 100 Each, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Alitretinoin Gel 0.1%, 60 GM, Unit-of-Use, Tube |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Digoxin Tab 125 MCG (0.125 MG), 100 Each, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Digoxin Tab 125 MCG (0.125 MG), 100 Each, Unit-Dose, Box |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Digoxin Tab 250 MCG (0.25 MG), 100 Each, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Digoxin Tab 62.5 MCG (0.0625 MG), 100 Each, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Donnatal Oral Elixir 16.2 MG/5ML 16.2-0.1037-0.0194-0.0065 MG/5ML, 480 ML, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Donnatal Oral Elixir 16.2 MG/5ML PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 120 ML, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 120 ML, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 480 ML, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | PB-Hyoscy-Atrop-Scopol Tab 16.2-0.1037-0.0194-0.0065 MG, 100 Each, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Prednisolone Sod Phos Orally Disintegr Tab 10 MG (Base Eq), 12 Each, Unit-Dose, Box |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Prednisolone Sod Phos Orally Disintegr Tab 15 MG (Base Eq), 12 Each, Unit-Dose, Box |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Prednisolone Sod Phos Orally Disintegr Tab 30 MG (Base Eq), 12 Each, Unit-Dose, Box |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Tranylcypromine Sulfate Tab 10 MG, 100 Each, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Triamterene Cap 100 MG, 100 Each, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Triamterene Cap 50 MG, 100 Each, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Zonisamide Cap 100 MG, 100 Each, Bottle |
|
|||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Zonisamide Cap 25 MG, 100 Each, Bottle |
|
|||
| Rx0000231 | American Health Packaging | 05/10/2024 | DOXYCYCLINE TABLET 100MG 30UD | 2810 | Market Conditions | No Change Improvement in the drug product | |
| Rx0000231 | American Health Packaging | 05/10/2024 | MESALAMINE DR CAP 400MG 20UD | 1775 | Market Conditions | No Change Improvement in the drug product | |
| Rx0000231 | American Health Packaging | 06/17/2024 | METHYLPHENIDATE HCL TABLET CII 5MG 30UD | 1237716 | Market Conditions | No Change Improvement in the drug product | |
| Rx0000231 | American Health Packaging | 05/10/2024 | RIFAMPIN CAPS 150MG 30UD | 1514 | Market Conditions | No Change Improvement in the drug product | |
| Rx0000231 | American Health Packaging | 05/10/2024 | RIFAMPIN CAPSULE 300MG 100UD | 4410 | Market Conditions | No Change Improvement in the drug product | |
| Rx0000128 | American Regent | 04/18/2024 | ACETYLCYSTEINE SOLUTION 10%, 4ML, PKG OF 25 | 1506925 | Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000128 | American Regent | 10/15/2024 | ACETYLCYSTEINE SOLUTION 10%, 4ML, PKG OF 25 | 9317500 | Cost Increase Factors Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000128 | American Regent | 04/02/2024 | Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk | 107470 | Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000128 | American Regent | 10/15/2024 | Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk | 2196112 | Cost Increase Factors Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000128 | American Regent | 10/15/2024 | Drug Product Description HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25 | 5130035 | Cost Increase Factors Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000128 | American Regent | 04/18/2024 | HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25 | 164000 | Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000128 | American Regent | 10/15/2024 | HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25 | 2597059 | Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000128 | American Regent | 04/18/2024 | HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25 | 200050 | Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000128 | American Regent | 10/15/2024 | Injectafer Intravenous Solution 750 MG/15ML | 396017525 | American Regents US Standards of Business Conduct (available at chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | There was no change or improvement | |
| Rx0000128 | American Regent | 10/15/2024 | MULTRYS (TRACE ELEMENTS INJECTION 4, USP, PKG. OF 25 | 13038815 | Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000128 | American Regent | 10/15/2024 | Tralement (TRACE ELEMENTS INJECTION 4, USP, PKG. OF 25 | 120117968 | Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. | No change or Improvement | |
| Rx0000069 | Amgen | 04/30/2024 | Aimovig, 140 mg/mL single-dose prefilled SureClick autoinjector |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Aimovig, 70 mg/mL single-dose prefilled SureClick autoinjector |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Blincyto, 35 mcg lyophilized vial, 1 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Corlanor, 5mg oral solution AMP, 28 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Corlanor, 5mg tablet, 60 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Corlanor, 7.5mg tablet, 60 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg (1 mL), Vial (EA), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg (1mL), Vial (EA), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg/0.5mL, Vial (EA), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 25mg/0.5mL, Vial (EA), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg/0.5mL, Vial (EA), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 25mg/0.5mL, Vial (EA), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 50mg/mL, Syringe (ML), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 50mg/mL, Syringe (ML), 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 50mg/mL, Syringe (ML), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 50mg/mL, Syringe (ML), 4 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Evenity, 105mg, 1.17mL prefilled syringe, 1 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Evenity, 105mg, 1.17mL prefilled syringe, 1 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Evenity, 105mg, 1.17mL prefilled syringe, 2 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Evenity, 105mg, 1.17mL prefilled syringe, 2 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Imlygic, 106 (1 million) PFU/mL (1.0 mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Imlygic, 108 (100 million) PFU/mL (1.0 mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Kyprolis, 60 mg lyophilized vial, 1 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Kyprolis, 60 mg lyophilized vial, 1 pk |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Lumakras, 120mg Tablet, 240 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Lumakras, 320mg Tablet, 90 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Otezla, 30mg, Tablet, 60 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Otezla, 30mg, Tablet, 60 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 10 mg/2 mL single-dose vial, 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 10 mg/2 mL single-dose vial, 10 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 2.5 mg/0.5 mL single-dose vial, 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 2.5 mg/0.5 mL single-dose vial, 10 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 5 mg/1 mL single-dose vial, 1 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 5 mg/1 mL single-dose vial, 10 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Repatha, 140 mg, 1.0 mL (140 mg/mL) autoinjector, 2 pack |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Repatha, 140 mg, 1.0 mL (140 mg/mL) prefilled syringe |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Repatha, 420 mg, 3.5 mL (120 mg/mL) Pushtronex system |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 04/30/2024 | Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000069 | Amgen | 07/25/2024 | Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial |
|
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access | ||
| Rx0000122 | Amneal Pharmaceuticals | 07/02/2024 | Budesonide Inhalation Suspension 0.25 MG/2ML 30 ampules |
|
|||
| Rx0000122 | Amneal Pharmaceuticals | 07/02/2024 | Budesonide Inhalation Suspension 0.5 MG/2ML 30 ampules |
|
|||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | BiDil 20mg/37.5mg 90 (Isosorbide Dinitrate/Hydralazine HCl Tablets) | 19473 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | EDARBI 40mg (azilsartan medoxomil) 30 tablets | 177504 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | EDARBI 80mg (azilsartan medoxomil) 30 tablets | 207890 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | EDARBYCLOR 40mg/12.5mg (azilsartan medoxomil / chlorthalidone) 30 tablets | 162303 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | EDARBYCLOR 40mg/25mg (azilsartan medoxomil / chlorthalidone) 30 tablets | 174135 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | Gliadel 7.7mg 8 Implant Wafers | 220 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | HORIZANT 300MG (gabapentin enacarbil) 30 extended-release tablets | 51678 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | HORIZANT 600MG (gabapentin enacarbil) 30 extended-release tablets | 151872 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | Nymalize 30mg/5mL prefilled oral syringe 12x5 ml | 35396 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | Nymalize 60mg/10ml Oral Solution 237ml 8oz | 3288 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | Nymalize 60mg/10mL prefilled oral syringe 12x10ml | 24942 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | SOTYLIZE 5mg/ml (sotalol hydrochloride) oral solution 250 ml | 6982 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | SOTYLIZE 5mg/ml (sotalol hydrochloride) oral solution 480ml | 2689 | Supply chain and market competition | N/A | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 10mg, 30 (Dextroamphetamine Sulfate Tablets) | 1889672 | Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including market dynamics, manufacturing and supply considerations, commercial and government rebates, patient support, inflation and cost of goods, cost of administrative and commercial activities, therapeutic class and patient population, as well as patient needs and access. | Price increase was not due to a change or improvement in the product | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 15mg, 30 (Dextroamphetamine Sulfate Tablets) | 2842448 | Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including market dynamics, manufacturing and supply considerations, commercial and government rebates, patient support, inflation and cost of goods, cost of administrative and commercial activities, therapeutic class and patient population, as well as patient needs and access. | Price increase was not due to a change or improvement in the product | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 2.5mg, 30 (Dextroamphetamine Sulfate Tablets) | 444629 | Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including market dynamics, manufacturing and supply considerations, commercial and government rebates, patient support, inflation and cost of goods, cost of administrative and commercial activities, therapeutic class and patient population, as well as patient needs and access. | Price increase was not due to a change or improvement in the product | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 20mg, 30 (Dextroamphetamine Sulfate Tablets) | 3850803 | Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including market dynamics, manufacturing and supply considerations, commercial and government rebates, patient support, inflation and cost of goods, cost of administrative and commercial activities, therapeutic class and patient population, as well as patient needs and access. | Price increase was not due to a change or improvement in the product | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 30mg, 30 (Dextroamphetamine Sulfate Tablets) | 2697988 | Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including market dynamics, manufacturing and supply considerations, commercial and government rebates, patient support, inflation and cost of goods, cost of administrative and commercial activities, therapeutic class and patient population, as well as patient needs and access. | Price increase was not due to a change or improvement in the product | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 5mg, 30 (Dextroamphetamine Sulfate Tablets) | 291126 | Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including market dynamics, manufacturing and supply considerations, commercial and government rebates, patient support, inflation and cost of goods, cost of administrative and commercial activities, therapeutic class and patient population, as well as patient needs and access. | Price increase was not due to a change or improvement in the product | |
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 7.5mg, 30 (Dextroamphetamine Sulfate Tablets) | 362584 | Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including market dynamics, manufacturing and supply considerations, commercial and government rebates, patient support, inflation and cost of goods, cost of administrative and commercial activities, therapeutic class and patient population, as well as patient needs and access. | Price increase was not due to a change or improvement in the product | |
| Rx0000359 | Ardelyx, Inc. | 04/23/2024 | Ibsrela Oral Tablet 50 MG, 60 Each, Unit-of-Use, Bottle |
|
|||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Cresemba, 186 mg / 14 capsules per blister pack |
|
|||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Cresemba, 372 mg / 1 vial |
|
|||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Xtandi, 40 mg / 120 capsules per bottle |
|
|||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Xtandi, 40 mg / 120 tablets per bottle |
|
|||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Xtandi, 80 mg / 60 tablets per bottle |
|
|||
| Rx0000015 | AstraZeneca | 07/25/2024 | LYNPARZA 120ct TABLET 100MG | 1253640792 | When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. | No changes to report, product launched on 08/18/2017 | |
| Rx0000015 | AstraZeneca | 07/25/2024 | LYNPARZA 120ct TABLET 150MG | 1253640792 | When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. | No changes to report, product launched on 08/18/2017 | |
| Rx0000015 | AstraZeneca | 07/25/2024 | LYNPARZA 60ct TABLET 100MG | 1253640792 | When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. | No changes to report, product launched on 08/17/2017 | |
| Rx0000015 | AstraZeneca | 07/25/2024 | LYNPARZA 60ct TABLET 150MG | 1253640792 | When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers. | No changes to report, product launched on 08/17/2017 | |
| Rx0000354 | AVEO Pharmaceuticals, Inc. | 04/24/2024 | Fotivda Oral Capsule 0.89 MG, 21 Each, Bottle |
|
|||
| Rx0000354 | AVEO Pharmaceuticals, Inc. | 10/25/2024 | Fotivda Oral Capsule 0.89 MG, 21 Each, Bottle |
|
|||
| Rx0000354 | AVEO Pharmaceuticals, Inc. | 04/24/2024 | Fotivda Oral Capsule 1.34 MG, 21 Each, Bottle |
|
|||
| Rx0000354 | AVEO Pharmaceuticals, Inc. | 10/25/2024 | Fotivda Oral Capsule 1.34 MG, 21 Each, Bottle |
|
|||
| Rx0000277 | Avion Pharmaceuticals, LLC | 04/23/2024 | Balcoltra Oral Tablet 0.1 - 20 mg/mcg pkg, size 1 - Insert |
|
Our price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute this product. | no changes | |
| Rx0000277 | Avion Pharmaceuticals, LLC | 04/23/2024 | Balcoltra Oral Tablet 0.1 - 20 mg/mcg pkg, size 3 |
|
Our price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute this product | no changes | |
| Rx0000108 | AvKare | 07/31/2024 | Ergocalciferol (vitamin D2) Capsule 1,250 mcg 100ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | Letrozole Tablet 2.5mg 90ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | losartan potassium/hydrochlorothiazide tablet 100 mg-12.5 mg 90ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | losartan potassium/hydrochlorothiazide tablet 100 mg-25 mg 90ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | Losartan potassium/hydrochlorothiazide tablet 50 mg-12.5 mg 90ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | Progesterone Capsule 100mg 100ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | Progesterone Capsule 200mg 100ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | Sulfamethoxazole/trimethoprim tablet 400 mg-80 mg 100ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | Sulfamethoxazole/trimethoprim tablet 400 mg-80 mg 500ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | Sulfamethoxazole/trimethoprim tablet 800 mg-160 mg 100ct |
|
|||
| Rx0000108 | AvKare | 07/31/2024 | Sulfamethoxazole/trimethoprim tablet 800 mg-160 mg 500ct |
|
|||
| Rx0000108 | AvKare | 04/29/2024 | URSODIOL 500MG TABLET 100ct |
|
|||
| Rx0000429 | Axsome Therapeutics, Inc. | 04/29/2024 | Sunosi Tablets 150mg 30 |
|
|||
| Rx0000429 | Axsome Therapeutics, Inc. | 04/29/2024 | Sunosi Tablets 75mg 30 |
|
|||
| Rx0000430 | Azurity Pharmaceuticals | 04/17/2024 | QBRELIS® (lisinopril) Oral Solution, 1 mg / mL, 150 mL | 7977323 | Supply chain and market competition | N/A | |
| Rx0000430 | Azurity Pharmaceuticals | 03/31/2024 | Xatmep 2.5/ml (methotrexate) Oral Solution 120ml | 2803 | Supply chain and market competition | N/A | |
| Rx0000430 | Azurity Pharmaceuticals | 03/31/2024 | Xatmep 2.5mg/ml (methotrexate) Oral Solution 60ml | 3742 | Supply chain and market competition | N/A | |
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 10mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 5mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | BEPREVE Ophthalmic Solution USP, 1.5%, 10mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | BEPREVE Ophthalmic Solution USP, 1.5%, 5mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | BESIVANCE® (besifloxacin ophthalmic suspension 0.6%), 5mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%), 5g |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%), 3.5g |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 10mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 15mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 5mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%, 5g |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | MIOCHOL®-E (acetylcholine chloride intraocular solution), 20mg/2 mL, Vial |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | PROLENSA (bromfenac ophthalmic solution) 0.07% 3mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION - New NDC), 0.50%, 0.3mL, 60ct |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL, 60ct |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | VYZULTA (latanoprostene bunod ophthalmic solution) 0.024%, 2.5mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | VYZULTA (latanoprostene bunod ophthalmic solution) 0.024%, 5mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | XIIDRA® (lifitegrast ophthalmic solution) 5%, 60ct |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ZIRGAN (Ganciclovir Ophthalmic Gel 0.15%), 5mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 10mL |
|
|||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 5mL |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ARAZLO (tazarotene) Lotion, 0.045%, 45g |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ATIVAN® Tablets 1mg 1,000s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ATIVAN® Tablets .5mg 100s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ATIVAN® Tablets 1mg 100s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ATIVAN® Tablets 2mg 100s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | BRYHALI (halobetasol propionate) Lotion 0.01%, 100g |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | BRYHALI (halobetasol propionate) Lotion 0.01%, 60g |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | DEMSER® (metyrosine), 250mg Capsules, 100ct |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, 1 |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | JUBLIA® (efinaconazole) Topical Solution 10%, 4mL |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | JUBLIA® (efinaconazole) Topical Solution 10%, 8mL |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MESTINON 60mg TABLETS 100s (pyridostigmine bromide) |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MYSOLINE 250 mg TABLETS, 100s (primidone) |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MYSOLINE 50 mg TABLETS, 100s (primidone) |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | SILIQ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes) |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 2.5mg Tablets, 90s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 10mg Tablets, 1,000s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 10mg Tablets, 30s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 10mg Tablets, 90s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 2.5mg Tablets, 30s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 20mg Tablets, 1,000s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 20mg Tablets, 30s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 20mg Tablets, 90s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 5mg Tablets, 30s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 5mg Tablets, 90s |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | WELLBUTRIN® XL 150mg Tablets, 30ct |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | WELLBUTRIN® XL 150mg Tablets, 90ct |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | WELLBUTRIN® XL 300mg Tablets, 30ct |
|
|||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ZELAPAR (selegiline HCI) 1.25mg Orally Disintegrating Tablets, 60ct |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.45% SODIUM CHL INJ,1000ML, 14 USPVIAFLEX PLASTIC CONTAINER |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% NACL INJ USP 50 ML, 96 MINI-BAG TM VIAFLEX CONT. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% NACL INJ USP, 100ML, 80 MINI-BAG PLUS CONT |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% NACL INJ. USP 100 ML, 96 MINI-BAG TM VIAFLEX CONT |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD CHL 100ML, 96 MINI-BAG VIAFLEX CONT |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD CHL IRRIG, USP, 3000ML ARTHROMATIC, 4 Plastic Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD CHL IRRIG, USP, 3000ML ARTHROMATIC, 4 Plastic Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD.CHL.IRRIG. USP 3000ML, 4 UROMATIC CONTAINER |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD.CHL.IRRIG. USP 3000ML, 4 UROMATIC CONTAINER |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 10% DEXTROSE INJECTION USP 250ML MIGRATED, 36 Flex Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 20 MEQ POT CHL IN .9% SOD CHLINJ,USP 1000ML, 14 Flex Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 20MEQ POT CHL IN 5% DEX&0.9%SOD CHL INJ, USP 1000ML, 14 Flex Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 5% DEX AND 0.45% SOD CHL INJ,USP 1000ML, 14 Flex Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 5% DEX AND 0.9% SOD CHL ING,USP 1000ML, 14 Flex Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 5% DEX INJ, USP, 100 ML , 80 MINI-BAG PLUS CONTAINER |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 5% DEX INJ, USP, 50ML, 80 MINI-BAG PLUS CONTAINER |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | DEXTROSE 5% INJECTION USP 1000ML MIGRATED, 14 flex cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | DEXTROSE 5% INJECTION USP 250ML MIGRATED, 36 Flex Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | LACTATED RINGERS & 5% DEXTROSEINJ, USP 1000ML, 14 Flex Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | LACTATED RINGERS IRRIG, 3000 ML ARTHROMATIC, 4 Plastic Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | NACL 0.9% INJ USP 50ML, 96 MINI-BAG TM VIAFLEX MIGRATED |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | PLASMA-LYTE A INJECTION PH 7.4MULTIPLE 1000ML 14 Flex Cont. |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | SOD CHLOR 0.9% INJ USP 100ML, 96 MINI- BAG TM VIAFLEX MIGRATED |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | SOD CHLOR 0.9% INJ USP 50ML, 80 MINI-BAG PLUS CONT MIGRATED |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | SOD CHLOR 0.9% INJ USP250ML, 36 VIAFLEXPLASTIC MIGRATED |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | STERILE WATER FOR INJ.USP 1000ML, 14 Flex Cont |
|
|||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | STERILE WATER FOR INJ.USP 1000ML, 14 Flex Cont |
|
|||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 0.5 MG TABLET 9 count | 721714 | Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 0.5 MG TABLET 90 count | 25109931 | Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 1 MG TABLET 9 count |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 1 MG TABLET 90 count | 45493959 | Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 1.5 MG TABLET 9 count |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 1.5 MG TABLET 90 count |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 2 MG TABLET 9 count |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 2 MG TABLET 90 count |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 2.5 MG TABLET 9 count |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 2.5 MG TABLET 90 count |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | BETASERON-01 |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | BETASERON-35 |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | Nexavar 200mg 120 Tablets | 33909045 | Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | Stivarga 40 mg tab 21 count bottle |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | Stivarga 40 mg tab 28 count bottle |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | Stivarga 40 mg tab 3x28 count bottle |
|
Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | Stivarga 40 mg tab 4x21 count bottle | 283617734 | Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | VITRAKVI 100MG CAPS BT 1x60 | 99855867 | Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | Vitrakvi 20 mg/mL oral solution | 6319883 | Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000024 | Bayer | 03/31/2024 | VITRAKVI 25MG CAPS BT 1x60 | 16562813 | Price setting and increases are part of the companys overall global competitive strategy and is developed by the companys senior leadership both in the U.S. and Globally. The ultimate factors considered in determining the price increase is on a need-to-know basis and known only to a handful of key global and U.S. executives. The information is not protected under patent or trademark laws and can be protected only by treating it as trade secret. Price setting has actual commercial value to the company and is key to competition in the market place and in obtaining competitive advantage over our competitors. It is not to the best interest of the public to disclose this information because such disclosure will reduce competition in the marketplace. | ||
| Rx0000103 | Biocodex USA | 03/31/2024 | Diacomit 250mg Capsule 60ct |
|
Due to inflation and operations costs a price increase is needed to offset escalating costs | ||
| Rx0000103 | Biocodex USA | 08/21/2024 | Diacomit 250mg Capsule 60ct |
|
|||
| Rx0000103 | Biocodex USA | 03/31/2024 | Diacomit 250mg Packet 60ct |
|
due to inflation and operations costs a price increase is needed to offset escalating costs | ||
| Rx0000103 | Biocodex USA | 08/21/2024 | Diacomit 250mg Packet 60ct |
|
|||
| Rx0000103 | Biocodex USA | 03/31/2024 | Diacomit 500mg Capsule 60ct |
|
due to inflation and operations costs a price increase is needed to offset escalating costs | ||
| Rx0000103 | Biocodex USA | 08/21/2024 | Diacomit 500mg Capsule 60ct |
|
|||
| Rx0000103 | Biocodex USA | 03/31/2024 | Diacomit 500mg Packet 60ct |
|
due to inflation and operations costs a price increase is needed to offset escalating costs | ||
| Rx0000103 | Biocodex USA | 08/21/2024 | Diacomit 500mg Packet 60ct |
|
|||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | BRINEURA 150 mg/5 mL INJ, Kit (Two 5 mL vials (30mg/ml) (IEV)-one 5ml vial) |
|
|||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | NAGLAZYME 1MG/ML INJ, (5 mL vial) |
|
|||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | PALYNZIQ 10MG/0.5ML INJ,SYR,0.5MLsingle-dose prefilled syringe |
|
|||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | PALYNZIQ 2.5MG/0.5ML INJ,SYR,0.5ML single-dose prefilled syringe |
|
|||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | PALYNZIQ 20MG/ML INJ,SYR,1ML single-dose prefilled syringe |
|
|||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | PALYNZIQ 20MG/ML INJ,SYR,1ML Ten 1 mL single- dose prefilled syringes |
|
|||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | VIMIZIM 1MG/ML INJ,SOLN,5ML vial |
|
|||
| Rx0000038 | Boehringer Ingelheim | 04/26/2024 | OFEV 100MG CAPSULE 60 |
|
|||
| Rx0000038 | Boehringer Ingelheim | 04/26/2024 | OFEV 150MG CAPSULE 60 |
|
|||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ABECMA® 250 mL infusion bag and metal cassette |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ABECMA® 50 mL infusion bag and metal cassette |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ABECMA® 500 mL infusion bag and metal cassette |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | BREYANZI® Carton up to 4 vials of cryopreserved CAR-positive T cells |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 2.5 mg tablet 60 count bottle |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 2.5 mg tablet pack of 100 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 5 mg tablet 60 count bottle |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 5 mg tablet 74 count bottle |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 5 mg tablet pack of 100 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 5 mg tablet pack of 74 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | IDHIFA® 100mg, 30 Tablets/Bottle |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | IDHIFA® 50mg, 30 Tablets/Bottle |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | INREBIC® 100mg, 120 Capsules/Bottle |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ONUREG® 200 mg tablet pack of 7 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ONUREG® 300 mg tablet pack of 7 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 125 mg Solution, 1ml Single Dose Prefilled Auto-injector, pack of 4 Auto-Injectors |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 125 mg Solution, 1ml Single Dose Prefilled Syringe, pack of 4 Syringes |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 250 mg lyophilized powder |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 10/15/2024 | ORENCIA® 250 mg lyophilized powder |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 50 mg/0.4ml Solution, 0.4ml Single Dose Prefilled Syringe, pack of 4 Syringes |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 87.5 mg/0.7ml Solution, 0.7ml Single Dose Prefilled Syringe, pack of 4 Syringes |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 1 mg capsule pack of 100 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 1 mg capsule pack of 21 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 2 mg capsule pack of 100 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 2 mg capsule pack of 21 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 3 mg capsule pack of 100 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 3 mg capsule pack of 21 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 4 mg capsule pack of 100 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 4 mg capsule pack of 21 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 100 mg tablet, bottle of 30 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 140 mg tablet, bottle of 30 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 20 mg tablet, bottle of 60 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 50 mg tablet, bottle of 60 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 70 mg tablet, bottle of 60 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 80 mg tablet, bottle of 30 |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ZEPOSIA® 0.23, 0.46MG TITR STR PCK 7CT US (Wallet) |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ZEPOSIA® 0.23,0.46,0.92MG 28CT KIT US |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ZEPOSIA® 0.92MG CAP 30CT BTL US |
|
We consider multiple factors when setting a list price for a medicine, including: The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply. | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Firdapse 10mg Tablet 240/Bottle |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Firdapse Blister shelf pack of 120 - 10mg tablets |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 0.05MG/ML Oral Suspension |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 0.05MG/ML Oral Suspension 340 |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 10mg Tablet |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 10mg Tablet 30 |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 12mg Tablet |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 12mg Tablet 30 |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 2mg Tablet |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 2mg Tablet 30 |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 4mg Tablet |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 4mg Tablet 30 |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 6mg Tablet |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 6mg Tablet 30 |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 8mg Tablet |
|
response to recent economic conditions and inflation | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 8mg Tablet 30 |
|
response to recent economic conditions and inflation | ||
| Rx0000139 | Chiesi USA | 04/11/2024 | Cleviprex injectable emulsion 25mg/50mL 10 vials in 1 box - Emulsion |
|
|||
| Rx0000139 | Chiesi USA | 04/11/2024 | Cleviprex injectable emulsion 50mg/100mL 10 vials in 1 box - Emulsion |
|
|||
| Rx0000139 | Chiesi USA | 04/09/2024 | Curosurf® 1.5ml 80mg/mL 1 1.5mL vial - Suspension |
|
|||
| Rx0000139 | Chiesi USA | 04/09/2024 | Curosurf® 3.0ml 80mg/mL 1 3.0mL vial - Suspension |
|
|||
| Rx0000139 | Chiesi USA | 04/08/2024 | Ferriprox ORAL SOLUTION 100mg/1mL 1 bottle of 500 mL - Solution |
|
|||
| Rx0000139 | Chiesi USA | 04/08/2024 | Ferriprox TD 1000mg FILM COATED TABLETS 1000mg 1 carton of 5 blister packs - Tablet |
|
|||
| Rx0000139 | Chiesi USA | 04/12/2024 | Juxtapid Oral Capsule 10 MG 1 package of 28 capsules - Capsule |
|
|||
| Rx0000139 | Chiesi USA | 04/12/2024 | Juxtapid Oral Capsule 20 MG 1 package of 28 capsules - Capsule |
|
|||
| Rx0000139 | Chiesi USA | 04/12/2024 | Juxtapid Oral Capsule 30 MG 1 package of 28 capsules - Capsule |
|
|||
| Rx0000139 | Chiesi USA | 04/12/2024 | Juxtapid Oral Capsule 5 MG 1 package of 28 capsules - Capsule |
|
|||
| Rx0000139 | Chiesi USA | 04/08/2024 | Kengreal for injection 50mg/10ML 50mg 1 box of 28 ampules - Solution |
|
|||
| Rx0000139 | Chiesi USA | 04/11/2024 | Myalept Subcutaneous Soltution Reconsituted 11.3 MG 1 vial - Injectable |
|
|||
| Rx0000139 | Chiesi USA | 04/10/2024 | Mycapssa 20mg 1 package of 28 capsules - Capsule |
|
|||
| Rx0000139 | Chiesi USA | 04/08/2024 | Revcovi® (elapegademase-IvIr 1.6mg/ml) Injection 1 vial 2.4mg/1.5mL - Solution |
|
|||
| Rx0000080 | Cipla USA, Inc. | 07/15/2024 | Griseofulvin Oral Suspension USP (microsize) 125mg/5ml, 120ml |
|
|||
| Rx0000320 | CMP Pharma | 03/31/2024 | Sodium Polystyrene Sulfonate, suspension, 15g/60ml, 10 BOTTLE in 1 CARTON 60 mL in 1 BOTTLE, |
|
Increasing costs related to inflationary environment materials, shipping, labor, overheads. A price increase is taken annually to keep up with inflation & rising costs. | The price increase is not necessitated by a change or improvement to the product. | |
| Rx0000320 | CMP Pharma | 03/31/2024 | Sodium Polystyrene Sulfonate, suspension, 15g/60mL, 120 mL in 1 BOTTLE |
|
Increasing costs related to inflationary environment materials, shipping, labor, overheads. A price increase is taken annually to keep up with inflation & rising costs. | The price increase is not necessitated by a change or improvement to the product. | |
| Rx0000320 | CMP Pharma | 03/31/2024 | Sodium Polystyrene Sulfonate, suspension, 15g/60ml, 473 mL in 1 BOTTLE |
|
Increasing costs related to inflationary environment materials, shipping, labor, overheads. A price increase is taken annually to keep up with inflation & rising costs. | The price increase is not necessitated by a change or improvement to the product. | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 150mg, 1 box of 60 films | 375967103 | |||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 300mg 1 box of 60 films | 375967103 | |||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 450mg, 1 box of 60 films | 375967103 | |||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 600mg, 1 box of 60 films | 375967103 | |||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 750mg, 1 box of 60 films | 375967103 | |||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 900mg, 1 box of 60 films | 375967103 | |||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca, 75mg, 1 box of 60 films | 375967103 | |||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta 100mg, tablet, 100 pack | 188776238 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucyntas manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta 50mg, tablet, 100 pack | 188776238 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucyntas manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta 75mg, tablet, 100 pack | 188776238 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucyntas manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 100mg, tablet, 60 pack | 141121033 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 150 mg, tablet, 60 pack | 141121033 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 200 mg, tablet, 60 pack | 141121033 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 250 mg, tablet, 60 pack | 141121033 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 50mg, tablet, 60 pack | 141121033 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Symproic 0.2 mg, 1 bottle of 30 tablets | 37753272 | |||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 13.5mg, capsule, 100 pack | 439178261 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 18mg, capsule, 100 pack | 439178261 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 27mg, capsule, 100 pack | 439178261 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 36mg, capsule, 100 pack | 439178261 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 9mg, capsule, 100 pack | 439178261 | While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. | ||
| Rx0000154 | Corcept Therapeutics Incorporated | 04/29/2024 | Korlym (mifepristone) 300mg Tablet (Bottle of 28) |
|
Corcept is committed to discovering, developing, and making available to patients and physicians, medicines that treat serious disorders for which there are very limited treatment options. In setting Korlyms price, among other factors, we weigh the increased cost of administrative and commercial activities; increased cost of research and development; and operating patient assistance programs. | none | |
| Rx0000154 | Corcept Therapeutics Incorporated | 04/29/2024 | Korlym (mifepristone) 300mg Tablet (Bottle of 280) |
|
Corcept is committed to discovering, developing, and making available to patients and physicians, medicines that treat serious disorders for which there are very limited treatment options. In setting Korlyms price, among other factors, we weigh the increased cost of administrative and commercial activities; increased cost of research and development; and operating patient assistance programs. | none | |
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Azor Tablets 10 mg/20 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Azor Tablets 10 mg/40 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Azor Tablets 5 mg/20 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Azor Tablets 5 mg/40 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar HCT Tablets 20 mg/12.5 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar HCT Tablets 40 mg/12.5 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar HCT Tablets 40 mg/25 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar Tablets 20 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar Tablets 40 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar Tablets 5 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 04/11/2024 | Clomid Tablets 50 mg 30-ct box |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 04/11/2024 | Clomid Tablets 50 ng 10-ct box |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Effient Tablets 10 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Effient Tablets 5 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 04/11/2024 | Migergot Suppositories 2-100 mg 12-ct box |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 20 mg/5 mg/12.5 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 40 mg/10 mg/12.5 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 40 mg/10 mg/25 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 40 mg/5 mg/12.5 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 40 mg/5 mg/25 mg |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Welchol for Oral Suspension 3.75 g |
|
|||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Welchol Tablets 625 mg |
|
|||
| Rx0000425 | CSL Behring LLC | 04/10/2024 | Berinert 500 units (500 IU / Solution / Pkg Size 1) |
|
CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | Not applicable | |
| Rx0000425 | CSL Behring LLC | 09/20/2024 | Berinert 500 units (500 IU / Solution / Pkg Size 1) |
|
|||
| Rx0000425 | CSL Behring LLC | 09/20/2024 | Haegarda 2000iu / 2000iu Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/20/2024 | Haegarda 3000iu / 3000iu Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 10 ml (2g) - inner / 2gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 10 ml (2g) PFS - inner / 2gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 10 ml (2g) PFS / 2gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 10 ml (2g) / 2gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 20 ml (4g) - inner / 4gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 20 ml (4g) PFS - inner / 4gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 20 ml (4g) PFS / 4gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 20 ml (4g) / 4gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 5 ml (1g) - inner / 1gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 5 ml (1g) / 1gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 5 ml (1g) PFS - inner / 1gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 5 ml (1g) PFS / 1gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 50 ml (10g) - inner / 10gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 50 ml (10g) / 10gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 50 ml (10g) PFS - inner / 10gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 50 ml (10g) PFS / 10gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 100ml (10g) - Inner / 10gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 100ml (10g) / 10gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 200ml (20g) - Inner / 20gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 200ml (20g) / 20gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 400ml (40g) - Inner / 40gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 400ml (40g) / 40gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 50ml (5g) - Inner / 5gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 50ml (5g) / 5gm Solution / UOM EA = 1 vial |
|
|||
| Rx0000230 | Cumberland Pharmaceuticals | 05/01/2024 | CALDOLOR VIALS 25 5mL VIA. |
|
Increase in cost of goods. | ||
| Rx0000230 | Cumberland Pharmaceuticals | 07/09/2024 | KRISTALOSE 10GM SOLD BY CASE (30 PACKETS) |
|
Increase is cost of goods. | ||
| Rx0000230 | Cumberland Pharmaceuticals | 07/09/2024 | KRISTALOSE 20GM SOLD BY CASE (30 PACKETS) |
|
Increase is cost of goods. | ||
| Rx0000230 | Cumberland Pharmaceuticals | 07/09/2024 | VIBATIV 750MG CASE OF 12 SINGLE DOSE VIALS |
|
Increase is cost of goods. | ||
| Rx0000216 | Deciphera Pharmaceuticals, LLC | 04/29/2024 | Qinlock Oral Tablet 50 MG, 90 Each, Bottle |
|
The establishment of price and associated price changes may take into consideration a number of factors such as current market dynamics, competitive environment, the clinical and economic value of therapy, therapeutic category, payer environment, government rebates, patient support, overall research and development costs, as well as business operational continuation needs. In our commitment to patients and ensuring patient access, we have a patient support program that provides reimbursement and financial assistance programs for eligible patients. | ||
| Rx0000216 | Deciphera Pharmaceuticals, LLC | 10/03/2024 | Qinlock Oral Tablet 50 MG, 90 Each, Bottle |
|
The establishment of price and associated price changes may take into consideration a number of factors such as current market dynamics, competitive environment, the clinical and economic value of therapy, therapeutic category, payer environment, government rebates, patient support, overall research and development costs, as well as business operational continuation needs. In our commitment to patients and ensuring patient access, we have a patient support program that provides reimbursement and financial assistance programs for eligible patients. | ||
| Rx0000492 | Dynavax Technologies Corporation | 03/31/2024 | HEPLISAV-B [Hepatitis B Vaccine (Recombinant)] Adjuvanted 20 MCG / 0.5 ML PFS Injection, Solution 5 SYRINGE in 1 CARTON (43528-003-05) / .5 mL in 1 SYRINGE (43528-003-01) |
|
|||
| Rx0000282 | Edenbridge Pharmaceuticals, LLC | 07/03/2024 | METHENAMINE MANDELATE - 0.5g Oral Tablet, 100ct Bottle [Qty: 1] |
|
|||
| Rx0000282 | Edenbridge Pharmaceuticals, LLC | 07/03/2024 | METHENAMINE MANDELATE -1g Oral Tablet, 100ct Bottle [Qty: 1] |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 10 & 4 MG Capsule Therapy Pack 10 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 10 MG & 2 x 4 MG Capsule Therapy Pack 15 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 10 MG Capsule Therapy Pack 5 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 2 x 10 MG & 4 MG Capsule Therapy Pack 15 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 10 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 2 x 4 MG Capsule Therapy Pack 10 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 15 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 90 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 4 MG Capsule Therapy Pack 30 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 4 MG Capsule Therapy Pack 5 EA UU |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib mesylate) 8 mg/day (4 mg x 2) 60 count |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib mesylate)10 mg/day (10 mg x 1) 30 count |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib mesylate)14 mg/day (10 mg x 1 and 4 mg x 1) 60 count |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib) 18 mg/day (10 mg x 1 and 4 mg x 2) 30 day supply |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib) 20 mg/day (10 mg x 2) 30 day supply |
|
|||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib) 24 mg/day (10 mg x 2 and 4 mg x 1) 30 day supply |
|
|||
| Rx0000114 | Eli Lilly and Company | 03/31/2024 | Verzenio Package Size: 14 Strength: 100 mg Dosage Form: TABLET |
|
|||
| Rx0000114 | Eli Lilly and Company | 03/31/2024 | Verzenio Package Size: 14 Strength: 150 mg Dosage Form: TABLET |
|
|||
| Rx0000114 | Eli Lilly and Company | 03/31/2024 | Verzenio Package Size: 14 Strength: 200 mg Dosage Form: TABLET |
|
|||
| Rx0000114 | Eli Lilly and Company | 03/31/2024 | Verzenio Package Size: 14 Strength: 50 mg Dosage Form: TABLET |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Cetrotide Subcutaneous Kit 0.25 MG, 1 Each, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (10 Tabs) Oral Tablet Therapy Pack 10 MG, 10 Each, Unit-of-Use, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (4 Tabs) Oral Tablet Therapy Pack 10 MG, 4 Each, Unit-of-Use, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (5 Tabs) Oral Tablet Therapy Pack 10 MG, 5 Each, Unit-of-Use, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (6 Tabs) Oral Tablet Therapy Pack 10 MG, 6 Each, Unit-of-Use, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (7 Tabs) Oral Tablet Therapy Pack 10 MG, 7 Each, Unit-of-Use, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (8 Tabs) Oral Tablet Therapy Pack 10 MG, 8 Each, Unit-of-Use, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (9 Tabs) Oral Tablet Therapy Pack 10 MG, 9 Each, Unit-of-Use, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Ovidrel Subcutaneous Injectable 250 MCG/0.5ML, .5 ML, Unit-Dose, Syringe |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Rebidose Subcutaneous Solution Auto-injector 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Rebidose Subcutaneous Solution Auto-injector 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Rebidose Titration Pack Subcutaneous Solution Auto-injector 6X8.8 & 6X22 MCG, 4.2 ML, Unit-of-Use, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Subcutaneous Solution Prefilled Syringe 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Subcutaneous Solution Prefilled Syringe 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Titration Pack Subcutaneous Solution Prefilled Syringe 6X8.8 & 6X22 MCG, 4.2 ML, Unit-of-Use, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Serostim Subcutaneous Solution Reconstituted 4 MG, 1 Each, Unit-Dose, Vial Qty 7 |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Serostim Subcutaneous Solution Reconstituted 5 MG, 1 Each, Unit-Dose, Vial Qty 7 |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Serostim Subcutaneous Solution Reconstituted 6 MG, 1 Each, Unit-Dose, Vial Qty 7 |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Tepmetko Oral Tablet 225 MG, 30 Each, Box |
|
|||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Tepmetko Oral Tablet 225 MG, 60 Each, Box |
|
|||
| Rx0000557 | Emmaus Medical, Inc. | 03/31/2024 | ENDARI [L-glutamine oral powder], 5g/1, Powder for solution, 1 powder for solution in 1 packet |
|
|||
| Rx0000557 | Emmaus Medical, Inc. | 03/31/2024 | ENDARI [L-glutamine oral powder], 5g/1, Powder for solution, 60 packet in 1 carton |
|
|||
| Rx0000091 | Endo Pharmaceuticals Inc. | 07/31/2024 | Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 10 MCG, 2 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 10 MCG, 6 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 20 MCG, 2 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 20 MCG, 6 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 40 MCG, 2 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 40 MCG, 6 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 500 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | THEO-24®, Theophylline Cap ER 24HR 100 MG, 100 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | THEO-24®, Theophylline Cap ER 24HR 200 MG, 100 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | THEO-24®, Theophylline Cap ER 24HR 300 MG, 100 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | THEO-24®, Theophylline Cap ER 24HR 400 MG, 100 |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 07/31/2024 | Valstar, 40 mg/1ml solution, 4x5mL |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 07/31/2024 | Xiaflex, 0.9mg powder for solution, single use vial |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000584 | Endo USA, Inc. | 07/31/2024 | BREVITAL SODIUM METHOHEXITAL SODIUM INJECTABLE 500MG/VIAL |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000584 | Endo USA, Inc. | 07/31/2024 | TIGAN TRIMETHOBENZAMIDE HYDROCHLORIDE INJECTABLE 100MG/ML, 25vl |
|
The price increase was not necessitated by a change or improvement in the drug. | ||
| Rx0000405 | Esperion | 03/31/2024 | Nexletol 30 Tab 180 mg/1 Tablet Film Coated |
|
Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions. | None | |
| Rx0000405 | Esperion | 03/31/2024 | Nexlizet 30 Tab 180 mg/1, 10 mg/1 Tablet Film Coated |
|
Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions. | None | |
| Rx0000270 | Eton Pharmaceuticals, Inc. | 04/25/2024 | Alkindi Sprinkle (hydrocortisone) Oral Granules 0.5 MG, 50 Capsules, Bottle |
|
Etons business has been impacted in recent years by inflation and the rising costs of its development efforts, operations and support. Eton has also been impacted by the increasing costs of patient support programs as well as PBM extended processes to approve coverage and unwillingness to approve prescribed drugs that are needed by patients. | ||
| Rx0000270 | Eton Pharmaceuticals, Inc. | 04/25/2024 | Alkindi Sprinkle (hydrocortisone) Oral Granules 1 MG, 50 Capsules, Bottle |
|
Etons business has been impacted in recent years by inflation and the rising costs of its development efforts, operations and support. Eton has also been impacted by the increasing costs of patient support programs as well as PBM extended processes to approve coverage and unwillingness to approve prescribed drugs that are needed by patients. | ||
| Rx0000270 | Eton Pharmaceuticals, Inc. | 04/25/2024 | Alkindi Sprinkle (hydrocortisone) Oral Granules 2 MG, 50 Capsules, Bottle |
|
Etons business has been impacted in recent years by inflation and the rising costs of its development efforts, operations and support. Eton has also been impacted by the increasing costs of patient support programs as well as PBM extended processes to approve coverage and unwillingness to approve prescribed drugs that are needed by patients. | ||
| Rx0000270 | Eton Pharmaceuticals, Inc. | 04/25/2024 | Alkindi Sprinkle (hydrocortisone) Oral Granules 5 MG, 50 Capsules, Bottle |
|
Etons business has been impacted in recent years by inflation and the rising costs of its development efforts, operations and support. Eton has also been impacted by the increasing costs of patient support programs as well as PBM extended processes to approve coverage and unwillingness to approve prescribed drugs that are needed by patients. | ||
| Rx0000455 | Evofem Biosciences, Inc. | 04/30/2024 | Phexxi Vaginal Gel 1.8-1-0.4%, 5 GM, Unit-of-Use, Box Qty 12 |
|
|||
| Rx0000010 | Exelixis, Inc. | 04/30/2024 | CABOMETYX 20MG 30 TAB BTL EACH |
|
Exelixis is driven by a singular focus to bring life-enhancing cancer treatments to patients. Throughout the past three decades, we have invested heavily in drug discovery and research and development (R&D) activities to evolve into the multi-platform cancer company we are today. In fact, since 2000 Exelixis has invested over 68% of its total revenue more than $5.3 billion into its R&D efforts, and is committed to spending the largest portion of its revenue on drug discovery research and clinical development. We are focused on innovating with both small molecules and biotherapeutics to build a diversified portfolio of potential cancer treatments, all with the goal of bringing the next generation of medicines and regimens to patients in need. This journey entails a high risk of failure, dedication to scientific excellence and a sense of urgency to translate learnings into meaningful advancements for patients. Exelixis plans moving forward are ambitious and include filing data-driven label expansions for CABOMETYX® with the U.S. Food and Drug Administration (FDA), accelerating the development of our robust pipeline through clinical trials, and moving three promising preclinical programs into clinical development in 2024. Drug Discovery and Pipeline Development Factors: The success of our internal drug discovery efforts has informed a rebalancing of our investment priorities from early-stage research to product development activities. These ambitious goals require a tremendous amount of capital, and at present, CABOMETYX® and COMETRIQ®, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis revenue. Exelixis considered the investments necessary to undertake and support these drug discovery and development efforts when it contemplated changes to the wholesale acquisition cost of CABOMETYX. Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in a broad and diverse collection of additional cancers, and invested large amounts of capital in late stage clinical trials to assess the efficacy of cabozantinib in additional tumors. Exelixis considered the cost of this clinical development program when it contemplated changes to the wholesale acquisition cost of CABOMETYX. CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with forms of kidney, liver and thyroid cancer, and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, we considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To ensure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, we considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising production costs and other operational costs due to high inflation. | It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX® when market conditions permit such an increase. | |
| Rx0000010 | Exelixis, Inc. | 04/30/2024 | CABOMETYX 40MG 30 TAB BTL EACH |
|
Exelixis is driven by a singular focus to bring life-enhancing cancer treatments to patients. Throughout the past three decades, we have invested heavily in drug discovery and research and development (R&D) activities to evolve into the multi-platform cancer company we are today. In fact, since 2000 Exelixis has invested over 68% of its total revenue more than $5.3 billion into its R&D efforts, and is committed to spending the largest portion of its revenue on drug discovery research and clinical development. We are focused on innovating with both small molecules and biotherapeutics to build a diversified portfolio of potential cancer treatments, all with the goal of bringing the next generation of medicines and regimens to patients in need. This journey entails a high risk of failure, dedication to scientific excellence and a sense of urgency to translate learnings into meaningful advancements for patients. Exelixis plans moving forward are ambitious and include filing data-driven label expansions for CABOMETYX® with the U.S. Food and Drug Administration (FDA), accelerating the development of our robust pipeline through clinical trials, and moving three promising preclinical programs into clinical development in 2024. Drug Discovery and Pipeline Development Factors: The success of our internal drug discovery efforts has informed a rebalancing of our investment priorities from early-stage research to product development activities. These ambitious goals require a tremendous amount of capital, and at present, CABOMETYX® and COMETRIQ®, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis revenue. Exelixis considered the investments necessary to undertake and support these drug discovery and development efforts when it contemplated changes to the wholesale acquisition cost of CABOMETYX. Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in a broad and diverse collection of additional cancers, and invested large amounts of capital in late stage clinical trials to assess the efficacy of cabozantinib in additional tumors. Exelixis considered the cost of this clinical development program when it contemplated changes to the wholesale acquisition cost of CABOMETYX. CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with forms of kidney, liver and thyroid cancer, and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, we considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To ensure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, we considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising production costs and other operational costs due to high inflation. | It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX® when market conditions permit such an increase. | |
| Rx0000010 | Exelixis, Inc. | 04/30/2024 | CABOMETYX 60MG 30 TAB BTL EACH |
|
Exelixis is driven by a singular focus to bring life-enhancing cancer treatments to patients. Throughout the past three decades, we have invested heavily in drug discovery and research and development (R&D) activities to evolve into the multi-platform cancer company we are today. In fact, since 2000 Exelixis has invested over 68% of its total revenue more than $5.3 billion into its R&D efforts, and is committed to spending the largest portion of its revenue on drug discovery research and clinical development. We are focused on innovating with both small molecules and biotherapeutics to build a diversified portfolio of potential cancer treatments, all with the goal of bringing the next generation of medicines and regimens to patients in need. This journey entails a high risk of failure, dedication to scientific excellence and a sense of urgency to translate learnings into meaningful advancements for patients. Exelixis plans moving forward are ambitious and include filing data-driven label expansions for CABOMETYX® with the U.S. Food and Drug Administration (FDA), accelerating the development of our robust pipeline through clinical trials, and moving three promising preclinical programs into clinical development in 2024. Drug Discovery and Pipeline Development Factors: The success of our internal drug discovery efforts has informed a rebalancing of our investment priorities from early-stage research to product development activities. These ambitious goals require a tremendous amount of capital, and at present, CABOMETYX® and COMETRIQ®, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis revenue. Exelixis considered the investments necessary to undertake and support these drug discovery and development efforts when it contemplated changes to the wholesale acquisition cost of CABOMETYX. Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in a broad and diverse collection of additional cancers, and invested large amounts of capital in late stage clinical trials to assess the efficacy of cabozantinib in additional tumors. Exelixis considered the cost of this clinical development program when it contemplated changes to the wholesale acquisition cost of CABOMETYX. CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with forms of kidney, liver and thyroid cancer, and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, we considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors. CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To ensure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, we considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising production costs and other operational costs due to high inflation. | It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer, and Exelixis is therefore engaged in a broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund these critical programs that may expand the use of cabozantinib, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX when market conditions permit such an increase. | |
| Rx0000193 | Forte Bio-Pharma, LLC | 07/11/2024 | NALOCET TABLETS 1 PACK 100 TABS 2.5 MG/300 MG |
|
Forte Bio considers many factors in the pricing of our products including but not limited to: - Constant competition in the marketplace requires frequent reassessments of pricing to ensure consistency with current market - Market share has a determining factor on our pricing as we determine our pricing structure to ensure our place in the market - Patient population contributes to each pricing decision as this helps determine the profitability of the product - The cost to market our products is continuously rising as we need more resources to properly market the products. | ||
| Rx0000193 | Forte Bio-Pharma, LLC | 07/11/2024 | PROLATE TABLETS 1 PACK 100 TABS 10 MG/300 MG |
|
Forte Bio considers many factors in the pricing of our products including but not limited to: - Constant competition in the marketplace requires frequent reassessments of pricing to ensure consistency with current market - Market share has a determining factor on our pricing as we determine our pricing structure to ensure our place in the market - Patient population contributes to each pricing decision as this helps determine the profitability of the product - The cost to market our products is continuously rising as we need more resources to properly market the products. | ||
| Rx0000193 | Forte Bio-Pharma, LLC | 07/11/2024 | PROLATE TABLETS 1 PACK 100 TABS 5 MG/300 MG |
|
Forte Bio considers many factors in the pricing of our products including but not limited to: - Constant competition in the marketplace requires frequent reassessments of pricing to ensure consistency with current market - Market share has a determining factor on our pricing as we determine our pricing structure to ensure our place in the market - Patient population contributes to each pricing decision as this helps determine the profitability of the product - The cost to market our products is continuously rising as we need more resources to properly market the products. | ||
| Rx0000193 | Forte Bio-Pharma, LLC | 07/11/2024 | PROLATE TABLETS 1 PACK 100 TABS 7.5 MG/300 MG |
|
Forte Bio considers many factors in the pricing of our products including but not limited to: - Constant competition in the marketplace requires frequent reassessments of pricing to ensure consistency with current market - Market share has a determining factor on our pricing as we determine our pricing structure to ensure our place in the market - Patient population contributes to each pricing decision as this helps determine the profitability of the product - The cost to market our products is continuously rising as we need more resources to properly market the products. | ||
| Rx0000260 | Galderma Laboratories | 04/10/2024 | TRI-LUMA Cream 24x30g US |
|
|||
| Rx0000034 | Genentech USA | 04/25/2024 | Alecensa 150 Mg - 240 Capsules |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | ||
| Rx0000034 | Genentech USA | 03/31/2024 | ENSPRYNG® (satralizumab-mwge) 120 mg/mL prefilled syringe |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | GAZYVA® (obinutuzumab) 1,000 mg/40 mL vial |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 07/24/2024 | KADCYLA® (ado-trastuzumab emtansine) 100 mg vial. Lyophilized powder in single-dose vials: 100 mg per vial of ado-trastuzumab emtansine. |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 07/24/2024 | KADCYLA® (ado-trastuzumab emtansine) 160 mg vial. Lyophilized powder in single-dose vials: 160 mg per vial of ado-trastuzumab emtansine. |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | KADCYLA® (ado-trastuzumab emtansine) 100 mg vial |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | KADCYLA® (ado-trastuzumab emtansine) 160 mg vial |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | PERJETA® (pertuzumab) 420 mg/14 mL vial |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 07/24/2024 | POLIVY® (polatuzumab vedotin-piiq) 140 mg Vial. POLIVY for injection is a sterile, preservative-free, white to grayish-white lyophilized powder, which has a cake-like appearance and is supplied in 140 mg single-dose vial. |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 07/24/2024 | POLIVY® (polatuzumab vedotin-piiq) 30 mg vial. POLIVY for injection is a sterile, preservative-free, white to grayish-white lyophilized powder, which has a cake-like appearance and is supplied in a 30 mg single-dose vial. |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | POLIVY® (polatuzumab vedotin-piiq) 30 mg vial |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | POLIVY® (polatuzumab vidotin-piiq) 140 mg vial |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | TNKase® (tenecteplase) 50 mg vial |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 07/24/2024 | TNKase® (tenecteplase) 50 mg vial. TNKase (tenecteplase for injection) is supplied as a sterile, lyophilized powder in a 50 mg, glass (20 cc) vial under partial vacuum. |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | XOLAIR® (omalizumab) 150 mg vial |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | XOLAIR® (omalizumab) 150 mg/mL syringe |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000034 | Genentech USA | 03/31/2024 | XOLAIR® (omalizumab) 75 mg/0.5 mL syringe |
|
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. | We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. | |
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | BIKTARVY (bictegravir sodium/emtricitabine/tenofovir alafenamide fumar 30 mg-120 mg-15 mg) tablet, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | BIKTARVY (bictegravir sodium/emtricitabine/tenofovir alafenamide fumar 50 mg-200 mg-25 mg) tablet, 30ct blister pack |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | BIKTARVY (bictegravir sodium/emtricitabine/tenofovir alafenamide fumar 50 mg-200 mg-25 mg) tablet, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | CAYSTON (aztreonam for inhalation solution) 75mg/vial, 84 vials/kit |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | COMPLERA (emtricitabine/rilpivirine HCl/tenofovir disoproxil fumarate 200 mg-25 mg-300 mg) tablet, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 150 mg-150 mg-200 mg-10 mg) tablet, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | LETAIRIS (ambrisentan 10 mg) tablet, 10ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | LETAIRIS (ambrisentan 10 mg) tablet, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | LETAIRIS (ambrisentan 5 mg) tablet, 10ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | LETAIRIS (ambrisentan 5 mg) tablet, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | ODEFSEY (emtricitabine/rilpivirine HCl/tenofovir alafenamide fumarate 200 mg-25 mg-25 mg) tablet, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil 150 mg-150 mg-200 mg-300 mg) tablet, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | TYBOST (cobicistat 150 mg) tablet, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | VEMLIDY (tenofovir alafenamide 25mg) tablets, 30ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | ZYDELIG (idelalisib 100 mg) tablet, 60ct bottle |
|
|||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | ZYDELIG (idelalisib 150 mg) tablet, 60ct bottle |
|
|||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Benlysta, Belimumab 200 MG/ML Solution Auto-injector 1 ML |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Benlysta, Belimumab 200 MG/ML Solution Auto-injector 1 ML X4 |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Benlysta, Belimumab 200 MG/ML Solution Prefilled Syringe 1 ML UD |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Benlysta, Belimumab 200 MG/ML Solution Prefilled Syringe 1 ML UD X4 |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Bexsero, Meningococcal Vac Group B (Recombant OMV Adjuvanted) Suspension Prefilled Syringe 0.5 ML UD |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Bexsero, Meningococcal Vac Group B (Recombant OMV Adjuvanted) Suspension Prefilled Syringe 0.5 ML UD X10 |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Nucala, Mepolizumab 100 MG/ML Solution Auto-injector 1 ML UD |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Nucala, Mepolizumab 100 MG/ML Solution Prefilled Syringe 1 ML UD |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Shingrix, Zoster Vaccine Recombinant Adjuvanted 50 MCG/0.5ML Suspension Reconstituted 1 EA UD |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Shingrix, Zoster Vaccine Recombinant Adjuvanted 50 MCG/0.5ML Suspension Reconstituted 1 EA UD X10 |
|
The price increase listed is not related to any identified or claimed change or improvement | ||
| Rx0000164 | Harmony Biosciences, LLC | 04/24/2024 | WAKIX pitolisant HCl 17.8 mg 30 Oral Tab |
|
|||
| Rx0000164 | Harmony Biosciences, LLC | 04/24/2024 | WAKIX pitolisant HCl 4.45 mg 30 Oral Tab |
|
|||
| Rx0000534 | Harrow Eye, LLC | 04/24/2024 | Ilevro Ophthalmic Suspension 0.3 % |
|
|||
| Rx0000534 | Harrow Eye, LLC | 07/18/2024 | Natamycin Ophth Susp 5%, 15 ML, Unit-of-Use, Bottle |
|
|||
| Rx0000534 | Harrow Eye, LLC | 04/24/2024 | Nevanac Ophthalmic Suspension 0.1 % |
|
|||
| Rx0000534 | Harrow Eye, LLC | 04/24/2024 | Triesence Intraocular Suspension 40 MG/ML |
|
|||
| Rx0000534 | Harrow Eye, LLC | 04/24/2024 | Verkazia Ophthalmic Emulsion 0.1 % |
|
|||
| Rx0000145 | Horizon Therapeutics USA, Inc. | 07/22/2024 | Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial |
|
|||
| Rx0000287 | Insmed Incorporated | 04/12/2024 | Arikayce Inhalation Suspension 590 MG/8.4ML |
|
|||
| Rx0000266 | Intercept Pharmaceuticals, Inc. | 04/02/2024 | Ocaliva - OBETICHOLIC ACID - 10mg Oral Tablet, 30ct bottle [Qty:1] |
|
|||
| Rx0000266 | Intercept Pharmaceuticals, Inc. | 04/02/2024 | Ocaliva - OBETICHOLIC ACID - 5mg Oral Tablet, 30ct bottle [Qty:1] |
|
|||
| Rx0000214 | Intra-Cellular Therapies, Inc. | 04/02/2024 | Caplyta Oral Capsule 42 MG 30 Pack |
|
ITI, Inc. consider multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply) | ||
| Rx0000084 | Ipsen Biopharmaceuticals, Inc. | 10/02/2024 | Drug product name: Onivyde. Drug product strength: 43 mg/10 mL (4.3 mg/mL). Drug product dosage form: vial. Drug product package size: 10 mL. |
|
|||
| Rx0000084 | Ipsen Biopharmaceuticals, Inc. | 03/31/2024 | Drug product name: Tazverik. Drug product strength: 200mg. Drug product dosage form: tablet. Drug product package size: 1 bottle (240 tablets). |
|
|||
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)Strength: 1800mg / 15 mL Package Size:1 Form:1 single vial |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000248 | Janssen Biotech, Inc. | 10/30/2024 | DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)Strength: 1800mg / 15 mL Package Size:1 Form:1 single vial |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | DARZALEX (daratumumab)Strength:100 mg 5 mL Package Size:1 Form:1 single vial |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000248 | Janssen Biotech, Inc. | 10/30/2024 | DARZALEX (daratumumab)Strength:100 mg 5 mL Package Size:1 Form:1 single vial |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | DARZALEX (daratumumab)Strength:400 mg 20 mL Package Size:1 Form:1 single vial |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000248 | Janssen Biotech, Inc. | 10/30/2024 | DARZALEX (daratumumab)Strength:400 mg 20 mL Package Size:1 Form:1 single vial |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | RYBREVANT (amivantamab-vmjw)Strength: 350mg/7mL Package Size:1 Form:1 single vial |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000248 | Janssen Biotech, Inc. | 07/30/2024 | RYBREVANT (amivantamab-vmjw)Strength: 350mg/7mL Package Size:1 Form:1 single vial |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | TREMFYA (guselkumab) One Press Injector Strength: 100mg / 1 mL Package Size:1 Form:1 syringe |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | TREMFYA (guselkumab) prefilled syringe Strength: 100mg / 1 mL Package Size:1 Form:1 syringe |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | ELMIRON® Strength:100 mg Package Size:100 Form:Capsule |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® HAFYERA® Strength:1092 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® HAFYERA® Strength:1560 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:117 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:156 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:234 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:39 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:78 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® TRINZA® Strength:273 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® TRINZA® Strength:410 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® TRINZA® Strength:546 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® TRINZA® Strength:819 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 07/30/2024 | PONVORY ® (ponesimod) Strength: 10 mg Package Size:14 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 07/30/2024 | PONVORY ® (ponesimod) Strength: 20 mg Package Size:30 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | SPRAVATO Strength:56 mg Package Size:2 Form:Nasal Spray |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | SPRAVATO Strength:84 mg Package Size:3 Form:Nasal Spray |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:3 MG Package Size:56 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:3 MG Package Size:84 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:4 MG Package Size:28 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:4 MG Package Size:56 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:5 MG Package Size:28 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | EDURANT (rilpivirine) Strength:25mg Package Size:30 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 07/30/2024 | EDURANT (rilpivirine) Strength:25mg Package Size:30 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | ERLEADA (apalutamide) Strength:60mg Package Size:120 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZCOBIX (darunavir 800mg, cobicistat 150mg) Strength:800 MG/150 MG Package Size:30 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® Strength:150 MG Package Size:240 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® Strength:600 MG Package Size:60 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® Strength:75 MG Package Size:480 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® Strength:800 MG Package Size:30 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® ORAL SUSPENSION Strength:100MG/mL Package Size:200mL Form:Oral Suspension |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000250 | Janssen Products, LP | 04/26/2024 | SYMTUZA (darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg) Strength: 800 MG/150 MG/200 MG/10 MG Package Size:30 Form:Tablet |
|
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. | Not Applicable | |
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 10/23/2024 | Defitelio (Defibrotide Sodium) Carton of 10 Vials |
|
|||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 04/26/2024 | Defitelio 200mg/2.5mL Solution 80mg/1mL |
|
Jazz Pharmaceuticals manufactures Specialty Pharmacy drugs for rare diseases that require a higher level of administration and effort to support patients. Product prices are determined by conducting extensive market research with Healthcare Providers (HCPs) to assess their perceptions of the clinical value delivered by our products. Jazz also evaluates relevant market analogues to support a price increase. Jazz engages its Pricing Committee to make price increase decisions. In doing so, the Pricing Committee balances capturing the product?s value with the priority of ensuring patient access. Specifically, the Pricing Committee considers the following factors in determining whether a price increase is warranted: ? Clinical value; ? HCP and Payer perceptions of a product?s clinical value; ? Patient access and affordability, in order to ensure our products are broadly available to HCPs and patients; ? Research and Development costs associated with production of the drug; ? Historic WAC price; ? Jazz?s fiduciary responsibility to its shareholders. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 10/23/2024 | RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection - 3 vial pack |
|
|||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 10/23/2024 | Vyxeos daunorubicin and cytarabine liposome for injection (2 vial carton) |
|
|||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 04/26/2024 | Xyrem 500 MG/ML Oral Solution 180 ml |
|
Jazz Pharmaceuticals manufactures Specialty Pharmacy drugs for rare diseases that require a higher level of administration and effort to support patients. Product prices are determined by conducting extensive market research with Healthcare Providers (HCPs) to assess their perceptions of the clinical value delivered by our products. Jazz also evaluates relevant market analogues to support a price increase. Jazz engages its Pricing Committee to make price increase decisions. In doing so, the Pricing Committee balances capturing the product?s value with the priority of ensuring patient access. Specifically, the Pricing Committee considers the following factors in determining whether a price increase is warranted: ? Clinical value; ? HCP and Payer perceptions of a product?s clinical value; ? Patient access and affordability, in order to ensure our products are broadly available to HCPs and patients; ? Research and Development costs associated with production of the drug; ? Historic WAC price; ? Jazz?s fiduciary responsibility to its shareholders. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 04/26/2024 | Xywav 500 MG/ML Oral Solution 180 ml |
|
Jazz Pharmaceuticals manufactures Specialty Pharmacy drugs for rare diseases that require a higher level of administration and effort to support patients. Product prices are determined by conducting extensive market research with Healthcare Providers (HCPs) to assess their perceptions of the clinical value delivered by our products. Jazz also evaluates relevant market analogues to support a price increase. Jazz engages its Pricing Committee to make price increase decisions. In doing so, the Pricing Committee balances capturing the product?s value with the priority of ensuring patient access. Specifically, the Pricing Committee considers the following factors in determining whether a price increase is warranted: ? Clinical value; ? HCP and Payer perceptions of a product?s clinical value; ? Patient access and affordability, in order to ensure our products are broadly available to HCPs and patients; ? Research and Development costs associated with production of the drug; ? Historic WAC price; ? Jazz?s fiduciary responsibility to its shareholders. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 10/23/2024 | Zepzelca (lurbinectedin) 4mg Vial |
|
|||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (100 MG Once Weekly) Oral Tablet Therapy Pack 50 MG, 2 Each, Unit-of-Use, Disp Pack Qty 4 |
|
|||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (40 MG Once Weekly) Oral Tablet Therapy Pack 40 MG, 1 Each, Unit-of-Use, Disp Pack Qty 4 |
|
|||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (40 MG Twice Weekly) Oral Tablet Therapy Pack 40 MG, 2 Each, Unit-of-Use, Disp Pack Qty 4 |
|
|||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (60 MG Once Weekly) Oral Tablet Therapy Pack 60 MG, 1 Each, Unit-of-Use, Disp Pack Qty 4 |
|
|||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (60 MG Twice Weekly) Oral Tablet Therapy Pack 20 MG, 6 Each, Unit-of-Use, Disp Pack Qty 4 |
|
|||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (80 MG Once Weekly) Oral Tablet Therapy Pack 40 MG, 2 Each, Unit-of-Use, Disp Pack Qty 4 |
|
|||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (80 MG Twice Weekly) Oral Tablet Therapy Pack 20 MG, 8 Each, Unit-of-Use, Disp Pack Qty 4 |
|
|||
| Rx0000264 | Kedrion Biopharma Inc. | 03/31/2024 | gammaked 10% carton w/ 1 x 100ml vial | 61663 | Rising cost of manufacturing | n/a | |
| Rx0000264 | Kedrion Biopharma Inc. | 03/31/2024 | gammaked 10% carton w/ 1 x 200ml vial | 83043 | Rising cost of manufacturing | n/a | |
| Rx0000264 | Kedrion Biopharma Inc. | 03/31/2024 | gammaked 10% carton w/ 1 x 50ml vial | 29504 | Rising cost of manufacturing | n/a | |
| Rx0000386 | KVK Tech, Inc. | 04/09/2024 | Lomaira Oral Tablet 8 MG 90ct | 4200000 | CPI increase | ||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | CRYSVITA (burosumab-twza) injection, for subcutaneous use, 10 mg/mL, 1 ML, single dose vial |
|
|||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | CRYSVITA (burosumab-twza) injection, for subcutaneous use, 20 mg/mL, 1 ML, single dose vial |
|
|||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | CRYSVITA (burosumab-twza) injection, for subcutaneous use, 30 mg/mL, 1 ML, single dose vial |
|
|||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | Nourianz Oral Tablet 20 MG, 90 Each, Bottle |
|
|||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | Nourianz Oral Tablet 40 MG, 90 Each, Bottle |
|
|||
| Rx0000083 | Laboratoire HRA Pharma | 06/17/2024 | Lysodren 500 mg tablets 100 count bottles |
|
Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors | ||
| Rx0000083 | Laboratoire HRA Pharma | 06/17/2024 | Metopirone 250 mg capsules 18 count bottles |
|
Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors | New manufacturer | |
| Rx0000089 | Lannett Company, Inc. | 10/30/2024 | Lisdexamfetamine Dimesylate 40mg Capsule 100 CT Bottle |
|
The increase in the WAC price is due to overall increased cost in business operations including, but not limited to, the increased cost to supply efficiently to patients due to supply chain constraints, additional overhead, and marketing costs. It is also due to market analysis and aiming to align with the average market price for competing products as well as supply chain disruptions and staffing challenges. | ||
| Rx0000089 | Lannett Company, Inc. | 10/30/2024 | Lisdexamfetamine Dimesylate 50mg Capsule 100 CT Bottle |
|
The increase in the WAC price is due to overall increased cost in business operations including, but not limited to, the increased cost to supply efficiently to patients due to supply chain constraints, additional overhead, and marketing costs. It is also due to market analysis and aiming to align with the average market price for competing products as well as supply chain disruptions and staffing challenges. | ||
| Rx0000089 | Lannett Company, Inc. | 10/30/2024 | Lisdexamfetamine Dimesylate 60mg Capsule 100 CT Bottle |
|
The increase in the WAC price is due to overall increased cost in business operations including, but not limited to, the increased cost to supply efficiently to patients due to supply chain constraints, additional overhead, and marketing costs. It is also due to market analysis and aiming to align with the average market price for competing products as well as supply chain disruptions and staffing challenges. | ||
| Rx0000089 | Lannett Company, Inc. | 10/30/2024 | Lisdexamfetamine Dimesylate 70mg Capsule 100 CT Bottle |
|
The increase in the WAC price is due to overall increased cost in business operations including, but not limited to, the increased cost to supply efficiently to patients due to supply chain constraints, additional overhead, and marketing costs. It is also due to market analysis and aiming to align with the average market price for competing products as well as supply chain disruptions and staffing challenges. | ||
| Rx0000009 | Lantheus Medical Imaging, Inc. | 04/12/2024 | DEFINITY US 16Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS |
|
|||
| Rx0000009 | Lantheus Medical Imaging, Inc. | 04/12/2024 | DEFINITY US 4Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS |
|
|||
| Rx0000009 | Lantheus Medical Imaging, Inc. | 04/12/2024 | NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection) |
|
|||
| Rx0000413 | Leadiant Biosciences, Inc. | 04/29/2024 | Cystaran Ophthalmic Solution 0.44 % |
|
|||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Northera 100mg. 90 Capsules |
|
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Northera 200mg. 90 Capsules |
|
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Northera 300mg. 90 Capsules |
|
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Onfi 10mg. 100 Tablets |
|
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Onfi 20mg. 100 Tablets |
|
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Onfi Oral Suspension 2.5mg/mL 120mL Bottle |
|
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." | ||
| Rx0000025 | Lundbeck LLC | 10/24/2024 | Vyepti 100mg/ml single dose vial |
|
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Xenazine 12.5mg. 112 Tablets |
|
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Xenazine 25.0mg. 112 Tablets |
|
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." | ||
| Rx0000072 | Mayne Pharma Inc | 07/26/2024 | Rhofade External Cream 1 %, 30 g, Unit-of-Use, Tube |
|
|||
| Rx0000382 | Melinta Therapeutics, LLC | 04/30/2024 | MINOCIN (Minocycline-Hydrochloride) is administered via intravenous form and packaged as 10 VIAL in 1 CARTON > 1 INJECTION in 1 VIAL (100 mg dose) |
|
Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision is ensure that all people who need our therapies will receive them. Melinta is committed to the responsible pricing of our products and our pricing methodology includes consideration of several financial and nonfinancial factors. Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in MINOCIN (minocycline) for Injection, as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary. | None - see cost increase factors statement. | |
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | BRIDION 10 200 mg/2 mL Vial (ML) |
|
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2023 and 2027 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $30.5 billion ($159 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. | There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. | |
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | BRIDION 10 500 mg/5 mL Vial (ML) |
|
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2023 and 2027 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $30.5 billion ($159 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. | There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. | |
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | DIFICID 1 packet granules (40mg/mL final concentration) Suspension-Reconsitituted-Oral (EA) |
|
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2023 and 2027 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $30.5 billion ($159 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. | There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. | |
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | DIFICID 20 200 mg Tablets |
|
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2023 and 2027 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $30.5 billion ($159 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. | There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. | |
| Rx0000138 | Merck Sharp & Dohme LLC | 09/26/2024 | GARDASIL 9 0.5 mL Syringes 10 |
|
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: . Capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2023 and 2027 including to increase manufacturing capacity. . Investments in research and development that last year alone totaled nearly $30.5 billion ($159 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. | There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. | |
| Rx0000138 | Merck Sharp & Dohme LLC | 09/26/2024 | GARDASIL 9 0.5 mL Vials 10 |
|
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: . Capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2023 and 2027 including to increase manufacturing capacity. . Investments in research and development that last year alone totaled nearly $30.5 billion ($159 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. | There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. | |
| Rx0000138 | Merck Sharp & Dohme LLC | 09/26/2024 | VARIVAX 0.5 mL Vials 10 |
|
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: . Capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2023 and 2027 including to increase manufacturing capacity. . Investments in research and development that last year alone totaled nearly $30.5 billion ($159 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. | There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. | |
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | ZERBAXA 10 1.5 gram Vial (EA) |
|
Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2023 and 2027 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $30.5 billion ($159 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people. | There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. | |
| Rx0000051 | MILLICENT U.S., INC. | 04/25/2024 | Femring (estradiol acetate vaginal ring) 0.1 mg/day, 1 Box |
|
|||
| Rx0000051 | MILLICENT U.S., INC. | 04/25/2024 | Femring (estradiol acetate vaginal ring) 0.05 mg/day, 1 Box |
|
|||
| Rx0000051 | MILLICENT U.S., INC. | 04/25/2024 | Intrarosa Prasterone Vaginal Inserts 6.5 mg per insert, 28 inserts per box |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Cimduo Tabs 300mg/300mg 30s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Depen (Penicillamine Tabs) 250mg 1s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Edluar 10mg Sublingual T 3x10 |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Edluar 10mg Sublingual T 5x6 |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Edluar 5mg Sublingual T 3x10 |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Edluar 5mg Sublingual T 5x6 |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | EMSAM TDS 12mg/day Bx30 |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | EMSAM TDS 6mg/day Bx30 |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | EMSAM TDS 9mg/day Bx30 |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Epifoam 1% 10g 1PK |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Gastrocrom Oral Concentrate 20mg/mL 5mL 96s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Levsin Tabs 0.125mg 100s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Levsin/SL Tabs 0.125mg 100s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | NuLev Chewable Melt Tabs 0.125mg 100s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Pretomanid Tabs 200mg 26s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Proctofoam HC 1% 10g 1PK |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Proctofoam NS 1% 15g |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Rowasa Kit Rectal Suspension 4g/60mL 28PK |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Rowasa Kit Rectal Suspension 4g/60mL 7PK |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Soma Tabs 250mg 30s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Soma Tabs 250mg100s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Soma Tabs 350mg 100s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Symfi Lo Tabs 400mg/300mg/300mg 30s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Symfi Tabs 600mg/300mg/300mg 30s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Tobramycin Inhalation Solution (Tobi) 300mg/5mL 56s |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Urelle Tabs 0.12mg/81mg/10.8mg/32.4mg/40.8mg 90s |
|
|||
| Rx0000046 | Mylan Specialty LP | 10/31/2024 | YUPELRI (Revefenacin) Inhalation Solution 175mcg/3mL 30PK |
|
|||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | YUPELRI Inhalation Solution 175mcg/3mL |
|
|||
| Rx0000476 | Neurelis | 03/31/2024 | 1 VALTOCO CARTON .5mg/.1ml VIAL, 1 Each, Unit-of-Use, Box Qty 2 |
|
Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or list prices are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential. | No Change or Improvement | |
| Rx0000476 | Neurelis | 03/31/2024 | 1 VALTOCO CARTON 10mg/.1ml VIAL, 1 Each, Unit-of-Use, Box Qty 2 |
|
Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or list prices are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential. | No Change or Improvement | |
| Rx0000476 | Neurelis | 03/31/2024 | VALTOCO CARTON with 10mg/.1ml VIALS, 1 Each, Unit-of-Use, Box Qty 2 |
|
Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or list prices are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential. | No Change or Improvement | |
| Rx0000476 | Neurelis | 03/31/2024 | VALTOCO CARTON with 7.5mg/.1ml VIALS, 1 Each, Unit-of-Use, Box Qty 2 |
|
Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or list prices are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential. | No Change or Improvement | |
| Rx0000420 | Nielsen BioSciences, Inc. | 03/31/2024 | Candin Injection Solution/1U in 0.1mL Intradermally/1mL Vial |
|
|||
| Rx0000420 | Nielsen BioSciences, Inc. | 03/31/2024 | Spherusol Injection Solution/Coccidioides immitis Spherule-Derived Skin Test Antigen - 1.27mcg/0.1mL/1mL Vial/0.1mL Intradermally/1ml multidose vial |
|
|||
| Rx0000204 | Noden Pharma USA, Inc. | 03/31/2024 | TEKTURNA 150MG TAB 30/EA |
|
|||
| Rx0000204 | Noden Pharma USA, Inc. | 03/31/2024 | TEKTURNA 300MG TAB 30/EA |
|
|||
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR DISPERZ TABLET FOR SUSPENSION 2 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR DISPERZ TABLET FOR SUSPENSION 3 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR DISPERZ TABLET FOR SUSPENSION 5 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR TABLET 10 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR TABLET 2.5 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR TABLET 5 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR TABLET 7.5 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX (2 SYRINGES) SYRINGE (ML) 150 mg/mL 1 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX SENSOREADY (2 PENS) PEN INJECTOR (ML) 150 mg/mL 1 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX SENSOREADY PEN PEN INJECTOR (ML) 150 mg/mL 1 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX SYRINGE SYRINGE (ML) 150 mg/mL 1 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX SYRINGE SYRINGE (ML) 75 mg/0.5 mL 0.5 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 160 mg-12.5 mg 90 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 160 mg-25 mg 90 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 320 mg-12.5 mg 90 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 320 mg-25 mg 90 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 80 mg-12.5 mg 90 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN TABLET 160 mg 90 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN TABLET 320 mg 90 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN TABLET 40 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN TABLET 80 mg 90 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 24 mg-26 mg 180 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 24 mg-26 mg 60 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 49 mg-51 mg 180 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 49 mg-51 mg 60 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 97 mg-103 mg 180 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 97 mg-103 mg 60 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 10 mg-160 mg-12.5 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 10 mg-160 mg-25 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 10 mg-320 mg-25 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 5 mg-160 mg-12.5 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 5 mg-160 mg-25 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE TABLET 10 mg-160 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE TABLET 10 mg-320 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE TABLET 5 mg-160 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE TABLET 5 mg-320 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXJADE TABLET, DISPERSIBLE 125 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXJADE TABLET, DISPERSIBLE 250 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXJADE TABLET, DISPERSIBLE 500 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | EXTAVIA KIT 0.3 mg 15 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | GILENYA CAPSULE 0.5 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 10/31/2024 | ILARIS VIAL (ML) 150 mg/mL 1 VIAL |
|
We price our medicines based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes. A worldwide slowdown in economic growth following the COVID-19 pandemic and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions. | ||
| Rx0000073 | Novartis | 04/26/2024 | JADENU SPRINKLE GRANULES IN PACKET (EA) 180 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | JADENU SPRINKLE GRANULES IN PACKET (EA) 360 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | JADENU SPRINKLE GRANULES IN PACKET (EA) 90 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | JADENU TABLET 180 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | JADENU TABLET 360 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | JADENU TABLET 90 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | KESIMPTA PEN PEN INJECTOR (ML) 20 mg/0.4 mL 0.4 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | KISQALI FEMARA CO-PACK TABLET 200 mg/day (200 mg x 1)-2.5 mg 49 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | KISQALI FEMARA CO-PACK TABLET 400 mg/day (200 mg x 2)-2.5 mg 70 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | KISQALI FEMARA CO-PACK TABLET 600 mg/day (200 mg x 3)-2.5 mg 91 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | KISQALI TABLET 200 mg/day (200 mg x 1) 21 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | KISQALI TABLET 400 mg/day (200 mg x 2) 42 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | KISQALI TABLET 600 mg/day (200 mg x 3) 63 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 07/31/2024 | KYMRIAH PLASTIC BAG, INJECTION (EA) 0.2 x 10exp6 to 2.5 x 10exp8 cell 1 |
|
We price our medicines based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes. A worldwide slowdown in economic growth following the COVID-19 pandemic and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions. | ||
| Rx0000073 | Novartis | 07/31/2024 | KYMRIAH PLASTIC BAG, INJECTION (EA) 0.6 x 10exp8 to 6 x 10exp8 cell 1 |
|
We price our medicines based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes. A worldwide slowdown in economic growth following the COVID-19 pandemic and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions. | ||
| Rx0000073 | Novartis | 04/26/2024 | MAYZENT TABLET 0.25 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | MAYZENT TABLET 2 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | MAYZENT TABLET, DOSE PACK 0.25 mg (12 tabs) 12 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | MEKINIST TABLET 0.5 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | MEKINIST TABLET 2 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | MYFORTIC TABLET, DELAYED RELEASE (ENTERIC COATED) 180 mg 120 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | MYFORTIC TABLET, DELAYED RELEASE (ENTERIC COATED) 360 mg 120 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | NEORAL CAPSULE 100 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | NEORAL CAPSULE 25 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | NEORAL SOLUTION, ORAL 100 mg/mL 50 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PIQRAY TABLET 200 mg/day (200 mg x 1) 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PIQRAY TABLET 250 mg/day (200 mg x 1 and 50 mg x 1) 56 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PIQRAY TABLET 300 mg/day (150 mg x 2) 56 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA POWDER IN PACKET (EA) 12.5 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA POWDER IN PACKET (EA) 25 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 12.5 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 25 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 50 mg 14 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 50 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 75 mg 30 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | RYDAPT CAPSULE 25 mg 112 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | RYDAPT CAPSULE 25 mg 56 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | SCEMBLIX TABLET 20 mg 60 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | SCEMBLIX TABLET 40 mg 60 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TABRECTA TABLET 150 mg 56 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TABRECTA TABLET 200 mg 56 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TAFINLAR CAPSULE 50 mg 120 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TAFINLAR CAPSULE 75 mg 120 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TASIGNA CAPSULE 150 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TASIGNA CAPSULE 200 mg 28 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TASIGNA CAPSULE 50 mg 120 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL SUSPENSION, ORAL (FINAL DOSE FORM) 100 mg/5 mL 450 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL TABLET 200 mg 100 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 100 mg 100 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 200 mg 100 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 400 mg 100 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TOBRADEX OINTMENT (GRAM) 0.3 %-0.1 % 3.5 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TRILEPTAL SUSPENSION, ORAL (FINAL DOSE FORM) 300 mg/5 mL (60 mg/mL) 250 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TRILEPTAL TABLET 150 mg 100 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TRILEPTAL TABLET 300 mg 100 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TRILEPTAL TABLET 600 mg 100 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | TYKERB TABLET 250 mg 150 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000073 | Novartis | 04/26/2024 | ZYKADIA TABLET 150 mg 84 |
|
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics | Not applicable | |
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 10 gm/100 mL single use vial |
|
Regular increase; unrecovered raw material increases over time | No change or improvement to the product necessitated the price increase. Please refer to Cost Increase Factor statement | |
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 2.5 gm/ 25 mL single use vial |
|
Regular increase; unrecovered raw material increases over time | No change or improvement to the product necessitated the price increase. Please refer to Cost Increase Factor statement | |
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 20 gm/200 mL single use vial |
|
Regular increase; unrecovered raw material increases over time | No change or improvement to the product necessitated the price increase. Please refer to Cost Increase Factor statement | |
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 30 gm/300 mL single use vial |
|
Regular increase; unrecovered raw material increases over time | No change or improvement to the product necessitated the price increase. Please refer to Cost Increase Factor statement | |
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 5 gm/50 mL single use vial |
|
Regular increase; unrecovered raw material increases over time | No change or improvement to the product necessitated the price increase. Please refer to Cost Increase Factor statement | |
| Rx0000375 | Organon | 07/18/2024 | Pregnyl Intramuscular Solution Reconstituted 10000 Unit Package of 1 Vial |
|
Organon is committed to providing a quality product that ensures the best possible outcomes for patients. Although this pricing change is not related to either a chemical change or functional improvement careful consideration and thorough research based on many factors were used to guide the decision to implement this action. Some of these factors include but are not limited to the cost advantages that are potentially provided for multiple areas across the healthcare continuum. The WAC history supplied includes historical pricing for this product prior to its divesture from Merck to Organon in 2021. | No change or improvement necessitated this pricing action | |
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Asimtufii 720mg Kit |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Asimtufii 960mg Kit |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Maintena 300mg Dual Chamber Syringe |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Maintena 300mg Kit |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Maintena 400mg Dual Chamber Syringe |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Maintena 400mg Kit |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 15mg tablets, 30 count bottle |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 15mg/15mg tablets, 4x weekly blister cards |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 30mg tablets, 30 count bottle |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 30mg/15mg tablets, 4x weekly blister cards |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 45mg/15mg tablets, 4x weekly blister cards |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 60mg/30mg tablets, 4x weekly blister cards |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 90mg/30mg tablets, 4x weekly blister cards |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Nuedexta 20mg/10mg CP, 60 count bottle |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 0.25mg tablets, 30 count bottle |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 0.5mg tablets, 30 count bottle |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 1mg tablets, 30 count bottle |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 2mg tablets, 30 count bottle |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 3mg tablets, 30 count bottle |
|
|||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 4mg tablets, 30 count bottle |
|
|||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 10 MG/0.4ML 1 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 10 MG/0.4ML 4 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 12.5 MG/0.4ML 1 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 12.5 MG/0.4ML 4 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 15 MG/0.4ML 1 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 15 MG/0.4ML 4 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 17.5 MG/0.4ML 1 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 17.5 MG/0.4ML 4 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 20 MG/0.4ML 1 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 20 MG/0.4ML 4 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 22.5 MG/0.4ML 1 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 22.5 MG/0.4ML 4 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 25 MG/0.4ML 1 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 25 MG/0.4ML 4 Syringe |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000484 | Pacira Pharmaceuticals, Inc. | 04/18/2024 | EXPAREL 13.3mg/mL Injection Suspension Liposomal 10 vials in 1 carton |
|
N/A | ||
| Rx0000484 | Pacira Pharmaceuticals, Inc. | 04/18/2024 | EXPAREL 13.3mg/mL Injection Suspension Liposomal 4 vials in 1 carton |
|
N/A | ||
| Rx0000053 | Paratek Pharmaceuticals, Inc. | 10/17/2024 | Nuzyra 100mg/5mL Intravenous Injection; Powder; Lyophilized 10 Carton |
|
|||
| Rx0000006 | Pfizer | 04/29/2024 | Acetylcysteine Solution Rx, 100 mg/mL (10 %), VIAL (ML), 30 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Acetylcysteine Solution Rx, 200 mg/mL (20 %), VIAL (ML), 30 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | ADD-Vantage, ADDapter Connector, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Aminophylline Injection Rx, 250 mg/10 mL, VIAL (ML), 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Antivenin (micrurus fulvius equine origin), 10mL, VIAL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, Ampul(ML), 5 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | ATROPINE SULFATE (atropine sulfate), 0.05 mg/mL, SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 1000 unit, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 2000 unit, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 250 unit, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 3000 unit, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 500 unit, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (900,000/300,000), SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BOSULIF (bosutinib), 100 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BOSULIF (bosutinib), 400 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BOSULIF (bosutinib), 500 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BRAFTOVI (encorafenib), 75 mg, CAPSULE, 120 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BRAFTOVI (encorafenib), 75 mg, CAPSULE, 180 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 1 mg/mL (1 mg/mL) Single Dose Glass Fliptop Vial, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (2 mg/mL) Single Dose Glass Fliptop Vial, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Cerebyx® (fosphenytoin sodium) Injection Rx, 100 mg PE/2 mL Vial, 25 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Cerebyx® (fosphenytoin sodium) Injection Rx, 500 mg PE/10 mL Vial, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | COPPER CHLORIDE (cupric chloride), 0.4 mg/mL, VIAL (ML), 25 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Demerol (meperidine hydrochloride) Injection - Controlled Substance - SCHEDULE II Rx, 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, VIAL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Dextran (dextran) Injection Rx, 500 mL (10% LMD in 0.9% Sodium Chloride), Intravenous solution, 12 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Dextran (dextran) Injection Rx, 500 mL (10% LMD in 5% Dextrose), Intravenous solution, 12 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Diazepam Injection - Controlled Substance - SCHEDULE IV Rx, 5 mg/mL, VIAL (ML), 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | DOPAMINE HCL (dopamine HCl), 200 mg/5 mL (40 mg/mL), VIAL (ML), 25 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | DOPAMINE HCL (dopamine HCl), 400 mg/10 mL (40 mg/mL), VIAL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Epinephrine Injection Rx, 1mg/10mL (0.1 mg/mL) ABBOJECT Single-dose syringe, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Gemcitabine Injection (Lyophilized) Rx, 200 mg, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Gentamicin Sulfate Injection Rx, 40 mg/mL (80 mg/2 mL) Single Dose Glass Fliptop Vial, 25 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 100 Units/mL (25,000 Units/250 mL) Flexible Container, 24 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 12500 unit/250 mL, INTRAVENOUS SOLUTION, 250 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 25000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 250 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 25000 unit/500 mL (50 unit/mL), INTRAVENOUS SOLUTION, 500 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | HEXTEND LACTATED ELECTROLYTE (hetastarch/electrolyte solution,lactated), 500mL, Vial, 12 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 100 mg, CAPSULE, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 100 mg, TABLET, 21 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 125 mg, CAPSULE, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 125 mg, TABLET, 21 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 75 mg, CAPSULE, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 75 mg, TABLET, 21 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | INLYTA (axitinib), 1 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | INLYTA (axitinib), 5 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | LORBRENA (lorlatinib), 100 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | LORBRENA (lorlatinib), 25 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | MANGANESE CHLORIDE (manganese chloride), 0.1 mg/mL, VIAL (ML), 25 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Mannitol Injection Rx, 25% (12.5 g/50 mL), Vial, 25 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine with Epinephrine 1:200,000 as the bitartrate (bupivacaine hydrochloride & epinephrine) Injection Rx, 2.5 mg/mL (25 mg/10 mL), Vial, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine with Epinephrine 1:200,000 as the bitartrate (bupivacaine hydrochloride & epinephrine) Injection Rx, 2.5 mg/mL (75 mg/30 mL), Vial, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine with Epinephrine 1:200,000 as the bitartrate (bupivacaine hydrochloride & epinephrine) Injection Rx, 5 mg/mL (50 mg/10 mL), Vial, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine (bupivacaine hydrochloride and epinephrine) Injection for NovaPlus, 2.5 mg/mL (0.25 %)-1:200000, VIAL (ML), 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine (bupivacaine hydrochloride and epinephrine) Injection for NovaPlus, 2.5 mg/mL (0.25 %)-1:200000, VIAL (ML), 30 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine (bupivacaine hydrochloride) Injection Rx, 2.5 mg/mL, VIAL (ML), 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | MEKTOVI (binimetinib), 15 mg, TABLET, 180 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection for NovaPlus® Rx, 10 mg/mL, AMPUL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection for NovaPlus® Rx, 10 mg/mL, AMPUL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection Rx, 10 mg/mL, AMPUL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection Rx, 10 mg/mL, AMPUL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection Rx, 20 mg/mL, AMPUL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Nipent (pentostatin) Injection Rx, 10 mg, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Oxbryta® (voxelotor) Tablets Rx, 300 mg, TABLET FOR SUSPENSION, 60 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Oxbryta® (voxelotor) Tablets Rx, 300 mg, TABLET FOR SUSPENSION, 90 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Oxbryta® (voxelotor) Tablets Rx, 500 mg, TABLET, 90 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | PIPERACILLIN-TAZOBACTAM (piperacillin sodium/tazobactam sodium), 13.5 gram, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | PLEGISOL (cardioplegic solution), 1000mL, PLASTIC BAG, PERFUSION (ML), 12 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Potassium Chloride Concentrate Injection Rx, 2 mEq/mL, VIAL (ML), 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Potassium Chloride Concentrate Injection Rx, 2 mEq/mL, VIAL (ML), 5 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.3 mg-1.5 mg, TABLET, 28 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | PREPIDIL (dinoprostone), 0.5 mg/3 gram, GEL WITH PREFILLED APPLICATOR (GRAM), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Sodium Bicarbonate Injection Rx, 4.2% (5mEq/10mL) per glass Abboject® syringe, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Sodium Bicarbonate Injection Rx, 7.5% (44/6 mEq/50mL) per glass Abboject® syringe, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Sodium Bicarbonate Injection Rx, 8.4% (10mEq/10mL) per glass vial Abboject® syringe, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Sodium Bicarbonate Injection Rx, 8.4% (50mEq/50mL) per glass Abbotject® syringe, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate) 500 mg/4 mL, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL EA, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL, VIAL EA 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF(hydrocortisone sodium succinate), 1000 mg/8 mL, VIAL EA 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Solu-Medrol® (methylprednisolone sodium succinate) Sterile Powder for Injection Rx, 2 gram, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 10 mg, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 15 mg, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 20 mg, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 25 mg, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 30 mg, VIAL (EA), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Talzenna® (talazoparib) Rx, 0.25 mg, CAPSULE, 30 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Talzenna® (talazoparib) Rx, 1 mg, CAPSULE, 30 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | THAM (tromethamine), 36 mg/mL (0.3 M), INTRAVENOUS SOLUTION, 6 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | TPN ELECTROLYTES (multiple electrolyte additive) Solution Rx, 20 mL, VIAL (ML), 25 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg / 0.5 mL, SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg/0.5 mL, SYRINGE (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Verapamil Hydrochloride Injection Rx, 2.5 mg/mL (10 mg/4 mL) Ansyr Plastic Syringe, 10 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, VIAL (ML) 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, VIAL (ML) 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, VIAL ML, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, VIAL ML, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL VIAL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL VIAL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL, VIAL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL, VIAL (ML), 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VIZIMPRO (dacomitinib), 15 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VIZIMPRO (dacomitinib), 30 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VIZIMPRO (dacomitinib), 45 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Vyndamax (tafamidis) Capsule Rx, 61 mg, CAPSULE, 30 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Vyndaqel® (tafamidis meglumine) Capsules Rx, 20 mg, CAPSULE, 120 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XALKORI (crizotinib), 200 mg, CAPSULE, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XALKORI (crizotinib), 250 mg, CAPSULE, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XELJANZ (tofacitinib citrate), 10 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XELJANZ (tofacitinib citrate), 5 mg, TABLET, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XELJANZ XR (tofacitinib citrate), 11 mg, TABLET, EXTENDED RELEASE 24 HR, 1 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XELJANZ XR (tofacitinib citrate), 22 mg, TABLET, EXTENDED RELEASE 24 HR, 30 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Xeljanz® (tofacitinib ) Oral Solution Rx, 1 mg/mL, SOLUTION ORAL, 240 |
|
A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors. | ||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | (DIPHENHYDRAMINE HYDROCHLORIDE) DIPHENHYDRAMINE HYDROCHLORIDE 12.5mg/5mL Oral Elixir, 5mL Cup [Qty: 1] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | DIPHENHYDRAMINE HYDROCHLORIDE (DIPHENHYDRAMINE HYDROCHLORIDE) 12.5mg/5mL Oral Elixir, 10mL Cup [Qty: 1] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | DIPHENHYDRAMINE HYDROCHLORIDE (DIPHENHYDRAMINE HYDROCHLORIDE) 12.5mg/5mL Oral Elixir, 10mL Cup [Qty: 100] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | DIPHENHYDRAMINE HYDROCHLORIDE (DIPHENHYDRAMINE HYDROCHLORIDE) 12.5mg/5mL Oral Elixir, 5mL Cup [Qty: 100] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 325mg/15mL;7.5mg/15mL Oral Solution, 5mL Cup [Qty: 1] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 325mg/15mL;7.5mg/15mL Oral Solution, 5mL Cup [Qty: 40] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 04/02/2024 | Lactulose Oral Solution 10 GM/15ML - 473mL Bottle [Qty: 1] |
|
|||
| Rx0000135 | Pharmaceutical Associates, Inc | 04/02/2024 | Lactulose Oral Solution 10 GM/15ML. - 946mL Bottle [Qty: 1] |
|
|||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE; CITRIC ACID) 500-334mg/5mL Oral Solution, 15mL Cup [Qty: 1] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE; CITRIC ACID) 500-334mg/5mL Oral Solution, 15mL Cup [Qty: 100] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE; CITRIC ACID) 500-334mg/5mL Oral Solution, 30mL Cup [Qty: 1] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE; CITRIC ACID) 500-334mg/5mL Oral Solution, 30mL Cup [Qty: 100] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SULFAMETHOXAZOLE-TRIMETHOPRIM (SULFAMETHOXAZOLE; TRIMETHOPRIM) |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SULFAMETHOXAZOLE-TRIMETHOPRIM (SULFAMETHOXAZOLE; TRIMETHOPRIM) 200-40mg/5mL Oral Suspension, 20mL Cup [Qty: 40] |
|
PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners. Comparison pricing was not used in this pricing decision. | No change or improvement | |
| Rx0000319 | Pharmacosmos Therapeutics | 03/31/2024 | Monoferric (ferric derisomaltose) Injection 1000mg/10mL 1 unit vial |
|
|||
| Rx0000410 | PharmaEssentia USA Corporation | 05/13/2024 | Besremi Subcutaneous Solution Prefilled Syringe 500 MCG/ML |
|
PharmaEssentia USA Corporation prices BESREMi using a variety of inforamtion and factors that are not public in nature and are related to confidential costs incurred coupled with expected drug utilization in a limited therapeutic class. Some factors that led to this increase in price include incremental costs of doing business, higher inflation of cost of goods, and increased participation and levels of discounting arrangements to government programs. | N/A | |
| Rx0000410 | PharmaEssentia USA Corporation | 03/31/2024 | Besremi Subcutaneous Solution Prefilled Syringe 500 MCG/ML, 1 1ML syringe per package |
|
PharmaEssentia USA Corporation prices BESREMi using a variety of inforamtion and factors that are not public in nature and are related to confidential costs incurred coupled with expected drug utilization in a limited therapeutic class. Some factors that led to this increase in price include incremental costs of doing business, higher inflation of cost of goods, and increased participation and levels of discounting arrangements to government programs | ||
| Rx0000469 | Pharming Healthcare Inc | 04/12/2024 | Ruconest 2100 U; Injection; Powder for Solution; 1 Carton |
|
|||
| Rx0000469 | Pharming Healthcare Inc | 04/12/2024 | Ruconest C1 Esterase Inhibitor (Recombinant) 2100 UNIT Solution Reconstituted 1 EA UD |
|
|||
| Rx0000589 | Prasco, LLC d/b/a Prasco Laboratories | 07/30/2024 | Spritam (levetiracetam) tablet, 1000mg, 6 x 10 |
|
The decision to increase the WAC involved a range of factors, including increased expenses, higher distribution costs and inflation. | Not applicable | |
| Rx0000589 | Prasco, LLC d/b/a Prasco Laboratories | 07/30/2024 | Spritam (levetiracetam) tablet, 250mg, 6 x 10 |
|
The decision to increase the WAC involved a range of factors, including increased expenses, higher distribution costs and inflation. | Not applicable | |
| Rx0000589 | Prasco, LLC d/b/a Prasco Laboratories | 07/30/2024 | Spritam (levetiracetam) tablet, 500mg, 6 x 10 |
|
The decision to increase the WAC involved a range of factors, including increased expenses, higher distribution costs and inflation. | Not applicable | |
| Rx0000589 | Prasco, LLC d/b/a Prasco Laboratories | 07/30/2024 | Spritam (levetiracetam) tablet, 750mg, 6 x 10 |
|
The decision to increase the WAC involved a range of factors, including increased expenses, higher distribution costs and inflation. | Not applicable | |
| Rx0000536 | Protega Pharmaceuticals, Inc. | 03/31/2024 | RoxyBond 15mg is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse even if the tablet is subjected to physical manipulation and/or chemical extraction. |
|
|||
| Rx0000536 | Protega Pharmaceuticals, Inc. | 03/31/2024 | RoxyBond 30mg is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse even if the tablet is subjected to physical manipulation and/or chemical extraction. |
|
|||
| Rx0000536 | Protega Pharmaceuticals, Inc. | 03/31/2024 | RoxyBond 5mg is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse even if the tablet is subjected to physical manipulation and/or chemical extraction. |
|
|||
| Rx0000220 | Puma Biotechnology, Inc. | 03/31/2024 | Nerlynx Oral Tablet 40 mg, 133 tablet package | 907 | Inflation has driven up costs in almost all areas of operations. | Not Applicable. | |
| Rx0000220 | Puma Biotechnology, Inc. | 03/31/2024 | Nerlynx Oral Tablet 40 mg, 180 tablet package | 10955 | Inflation has driven up costs in almost all areas of operations. | Not Applicable. | |
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 10MG TABLETS 100S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 10MG TABLETS HUD 20S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 15MG TABLETS 100S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 15MG TABLETS HUD 20S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 20MG TABLETS 100S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 20MG TABLETS HUD 20S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 30MG TABLETS 100S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 30MG TABLETS HUD 20S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 40MG TABLETS 100S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 40MG TABLETS HUD 20S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 60MG TABLETS 100S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 60MG TABLETS HUD 20S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 80MG TABLETS 100S |
|
None | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 80MG TABLETS HUD 20S |
|
None | ||
| Rx0000342 | PureTek Corporation | 07/16/2024 | Davimet with Fluoride 0.75mg, chewable multivitamin, Grape flavor, 30 tablets, Vit A, Vit C, Vit D3, Vit. E, Thiamin, Riboflavin, Niacin, Vit. B6, Folate, Vit. B12, Fluoride |
|
|||
| Rx0000342 | PureTek Corporation | 07/16/2024 | Hydroxate Gel, gel, hydrocortisone 2%, 1oz |
|
|||
| Rx0000342 | PureTek Corporation | 07/16/2024 | Hydroxym Cream, Anti-itch cream, hydrocortisone 2%, 1oz |
|
|||
| Rx0000356 | Radius Health, Inc. | 03/31/2024 | TYMLOS 80 MCG Pen |
|
|||
| Rx0000356 | Radius Health, Inc. | 03/31/2024 | TYMLOS 80 MCG Pen / Carton |
|
|||
| Rx0000363 | Recordati Rare Diseases, inc. | 12/13/2024 | Sylvant Intravenous Solution Reconstituted 100 MG 1 Vial |
|
|||
| Rx0000363 | Recordati Rare Diseases, inc. | 12/13/2024 | Sylvant Intravenous Solution Reconstituted 400 MG 1 Vial |
|
|||
| Rx0000166 | Redhill Biopharma, Inc. | 04/22/2024 | Talicia, Amoxicillin-Rifabutin-Omeprazole Cap DR 250-12.5-10 MG, 84 Each, Unit-of-Use, Bottle |
|
|||
| Rx0000166 | Redhill Biopharma, Inc. | 04/22/2024 | Talicia, Amoxicillin-Rifabutin-Omeprazole Cap DR 250-12.5-10 MG, 84 Each, Unit-of-Use, Bottle Qty 2 |
|
|||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Dronabinol Capsules 2.5mg 60s |
|
None | ||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Hydromorphone HCL 4mg Tablets 100s |
|
None | ||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Hydromorphone HCL 8mg Tablets 100s |
|
None | ||
| Rx0000563 | Rhodes Pharmaceuticals LP | 04/23/2024 | Morphine Sulfate ER 15mg Tablets 100s |
|
None | ||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Oxycodone Hydrochloride 20mg Tablets 100s |
|
None | ||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Oxycodone Hydrochloride 30mg Tablets 100s |
|
None | ||
| Rx0000239 | Rigel Pharmaceuticals, Inc. | 04/04/2024 | TAVALISSE TAB 100MG 60 TABS |
|
Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs | This WAC increase is not necessitated by a change or improvement in the prescription drug. | |
| Rx0000239 | Rigel Pharmaceuticals, Inc. | 04/04/2024 | TAVALISSE Tab 150MG 60 TABS |
|
Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs | This WAC increase is not necessitated by a change or improvement in the prescription drug. | |
| Rx0000158 | RISING PHARMA HOLDINGS, INC. | 04/05/2024 | METHIMAZOLE TAB 10 MG 100CT | 130000 | Reduce purchases of product in secondary market. The product is multisource and available from other suppliers. Rising has less than a quarter share of the market. | Not Applicable | |
| Rx0000158 | RISING PHARMA HOLDINGS, INC. | 04/05/2024 | METHIMAZOLE TAB 5 MG 100CT | 270000 | Reduce purchases of product in secondary market. The product is multisource and available from other suppliers. Rising has less than a quarter share of the market. | Not Applicable | |
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | COLAZAL® (balsalazide disodium) 750mg Capsules, 280ct BTL |
|
|||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial |
|
|||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct |
|
|||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial |
|
|||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct |
|
|||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) Tablets 150mg, 90ct |
|
|||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | Trulance® (plecanatide) 3mg Tablets, 30 |
|
|||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card |
|
|||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | XIFAXAN® (rifaximin) 550mg Tablets, 60ct |
|
|||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | CILOXAN OINTMENT 0.3% 3.5G 1EOIN US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | HYCAMTIN 0.25MG 10HGC US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | HYCAMTIN 1MG 10HGC US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | HYCAMTIN 4MG 1LYVI US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LESCOL XL 80MG 30TAB US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LOTREL 10+20MG 100HGC BO US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LOTREL 10+40MG 100HGC BO US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LOTREL 5+10MG 100HGC BO US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LOTREL 5+20MG 100HGC BO US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RECLAST 5MG/100ML 1LIVI US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN IR 10MG 100TAB BO US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN IR 20MG 100TAB BO US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN IR 5MG 100TAB BO US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN LA 10MG 100PRCH US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN LA 20MG 100PRCH US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN LA 30MG 100PRCH US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN LA 40MG 100PRCH US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | TRAVATAN Z SOL .004% 2.5ML LDP US |
|
Market conditions and dynamics | N/A | |
| Rx0000027 | Sandoz Inc. | 04/02/2024 | TRAVATAN Z SOL .004% 5ML LDP US |
|
Market conditions and dynamics | N/A | |
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 100 mg/0.67 mL (0.67 mL/syringe) - 2 syringes |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 200 mg/1.14 mL (1.14 mL/pen) - 2 pens |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 200 mg/1.14 mL (1.14 mL/syringe) - 2 syringes |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 300 mg/2 mL (2 mL/pen) - 2 pens |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 300 mg/2 mL (2 mL/syringe) - 2 syringes |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 10/30/2024 | Jevtana® (cabazitaxel) Injection Concentrate) 60mg vial, 1.5ml carton |
|
Sanofis pricing actions align to our Pricing Principles, which balances ensuring patients have access to the medicines they need now and in the future, adherence to government policies, and the need to respond to evolving trends in the marketplace. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles | ||
| Rx0000011 | Sanofi | 04/30/2024 | KEVZARA® (sarilumab) 150 mg/1.14 mL pen - carton of 2 pens |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 04/30/2024 | KEVZARA® (sarilumab) 150 mg/1.14 mL syringe - carton of 2 syringes |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 04/30/2024 | KEVZARA® (sarilumab) 200 mg/1.14 mL pen - carton of 2 pens |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 04/30/2024 | KEVZARA® (sarilumab) 200 mg/1.14 mL syringe - carton of 2 syringes |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 04/30/2024 | MenQuadfi® (Meningococcal tetanus conjugate vaccine)10 mcg/0.5 mL (0.5 mL dose/vial) - 5 vials |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 10/30/2024 | Typhim Vi® (Typhoid vaccine) 0.5 mL (1-dose) syringe |
|
Sanofis pricing actions align to our Pricing Principles, which balances ensuring patients have access to the medicines they need now and in the future, adherence to government policies, and the need to respond to evolving trends in the marketplace. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles | ||
| Rx0000011 | Sanofi | 10/30/2024 | Typhim Vi® (Typhoid vaccine) 10 mL (0.5 mL dose) vial |
|
Sanofis pricing actions align to our Pricing Principles, which balances ensuring patients have access to the medicines they need now and in the future, adherence to government policies, and the need to respond to evolving trends in the marketplace. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles | ||
| Rx0000011 | Sanofi | 04/30/2024 | Typhim Vi® (Typhoid vaccine)25 mcg/0.5 mL (0.5 ml dose/10 mL vial) - 1 vial |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 04/30/2024 | Typhim Vi® (Typhoid vaccine)25 mcg/0.5 mL (0.5 ml dose/syringe) - 1 syringe |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000011 | Sanofi | 10/30/2024 | YF-VAX® (Yellow fever vaccine) 0.5 mL (1-dose) vial |
|
Sanofis pricing actions align to our Pricing Principles, which balances ensuring patients have access to the medicines they need now and in the future, adherence to government policies, and the need to respond to evolving trends in the marketplace. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles | ||
| Rx0000011 | Sanofi | 04/30/2024 | YF-VAX® (Yellow fever vaccine)10 exp4.74 unit/0.5 mL (0.5 mL dose/vial) - 5 vials |
|
Sanofi is an industry leader in responsible pricing and our we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. Our 2024 pricing actions are consistent with our publicly available Pricing Principles, which balances our drive to ensure patients have access to the medicines they need now and in the future, our adherence to government policies, and the need to respond to evolving trends in the marketplace. | ||
| Rx0000092 | Santarus, Inc. | 04/28/2024 | CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct |
|
|||
| Rx0000086 | Seagen, Inc. | 07/18/2024 | ADCETRIS, 50mg, single-dose vial, packaged singly |
|
|||
| Rx0000086 | Seagen, Inc. | 04/26/2024 | PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution |
|
|||
| Rx0000086 | Seagen, Inc. | 04/26/2024 | PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution |
|
|||
| Rx0000086 | Seagen, Inc. | 04/26/2024 | TIVDAK (tisotumab vedotin-tftv) 40mg/vial, Lyophilized Powder in a single-dose vial for reconstitution |
|
|||
| Rx0000086 | Seagen, Inc. | 10/31/2024 | TIVDAK (tisotumab vedotin-tftv) 40mg/vial, Lyophilized Powder in a single-dose vial for reconstitution |
|
|||
| Rx0000028 | Servier Pharmaceuticals LLC | 04/24/2024 | Oncaspar Injection Solution 750 UNIT/ML, 5 ML, Unit-Dose, Vial |
|
|||
| Rx0000028 | Servier Pharmaceuticals LLC | 04/24/2024 | Tibsovo Oral Tablet 250 MG, 60 Each, Bottle |
|
|||
| Rx0000175 | Sobi Inc | 04/12/2024 | KINERET (anakinra) 100 MG/0.67 ML SYRINGE. 7 syringes in 1 carton (.67 ML in 1 syringe). |
|
Sobi, Inc., pricing decisions regarding the Wholesale Acquisition Cost (WAC) price of medication are determined after careful consideration of several interdependent factors, including but not limited to the clinical and economic value of the medicine. | This WAC increase is not necessitated by a change or improvement in the prescription drug. | |
| Rx0000244 | Sprout Pharmaceuticals, Inc. | 09/09/2024 | ADDYI (FLIBANSERIN) 100mg Oral Tablet, 30ct Bottle - [Qty:1] |
|
This pricing decision was based upon strategic and economic review, taking into consideration managed care and cash pay marketplace changes, costs of production, marketing, salaries and distribution; as well as increased regulatory pressure. Addyi is an FDA-approved prescription medicine used to treat hypoactive sexual desire disorder (HSDD) in women. Sprout Pharmaceuticals, Inc. has partnered with a specialty pharmacy to offer the best experience and economic value for patients. | No Change/Approvement | |
| Rx0000005 | Sumitomo Pharma America, Inc. | 04/02/2024 | Aptiom 30 Oral Tablets 200 MG |
|
Sumitomo Pharma America, Inc. has made the decision to increase the WAC price of the applicable product effective January 1 2024. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months. | No change or improvement | |
| Rx0000005 | Sumitomo Pharma America, Inc. | 04/02/2024 | Aptiom 30 Oral Tablets 400 MG |
|
Sumitomo Pharma America, Inc. has made the decision to increase the WAC price of the applicable product effective January 1 2024. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months. | No change or improvement | |
| Rx0000005 | Sumitomo Pharma America, Inc. | 04/02/2024 | Aptiom 30 Oral Tablets 800 MG |
|
Sumitomo Pharma America, Inc. has made the decision to increase the WAC price of the applicable product effective January 1 2024. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months. | No change or improvement | |
| Rx0000005 | Sumitomo Pharma America, Inc. | 04/02/2024 | Aptiom 60 Oral Tablets 600 MG |
|
Sumitomo Pharma America, Inc. has made the decision to increase the WAC price of the applicable product effective January 1 2024. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months. | No change or improvement | |
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Oxtellar XR Oral Tablet Extended Release 24 Hour 150 MG Package Size 100 Package Qty 1 |
|
|||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Oxtellar XR Oral Tablet Extended Release 24 Hour 300 MG Package Size 100 Package Qty 1 |
|
|||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Oxtellar XR Oral Tablet Extended Release 24 Hour 600 MG Package Size 100 Package Qty 1 |
|
|||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Qelbree Oral Capsule Extended Release 24 Hour 100 MG Package Size 30 Package Qty 1 |
|
|||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Qelbree Oral Capsule Extended Release 24 Hour 150 MG Package Size 30 Package Qty 1 |
|
|||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Qelbree Oral Capsule Extended Release 24 Hour 200 MG Package Size 30 Package Qty 1 |
|
|||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG 180 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG 180 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG 30 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG 30 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG 90 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG 90 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG 90 MG TABLET * 7 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG 90 MG TABLET * 7 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG INITIATION PACK - 7 CT 90 MG TABLET and 23 CT 180 MG TABLET - PER PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG INITIATION PACK - 7 CT 90 MG TABLET and 23 CT 180 MG TABLET - PER PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/15/2024 | Entyvio Intravenous Solution Reconstituted 300 MG |
|
|||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ICLUSIG 10 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ICLUSIG 10 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ICLUSIG 15 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ICLUSIG 15 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ICLUSIG 30 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ICLUSIG 30 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ICLUSIG 45 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ICLUSIG 45 MG TABLET * 30 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 2.3 MG CAPSULE * 3 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 2.3 MG CAPSULE * SINGLE PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 3.0 MG CAPSULE * 3 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 4.0 MG CAPSULE * 3 PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 4.0 MG CAPSULE * SINGLE PACK |
|
NA | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 3.0 MG CAPSULE * SINGLE PACK |
|
NA | ||
| Rx0000232 | TerSera Therapeutics LLC | 04/30/2024 | Xermelo Oral Tablet 250 MG, 84 Each, Unit-of-Use, Box |
|
|||
| Rx0000232 | TerSera Therapeutics LLC | 04/30/2024 | Zoladex Subcutaneous Implant 10.8 MG, 1 Each, Unit-of-Use, Box |
|
|||
| Rx0000232 | TerSera Therapeutics LLC | 10/30/2024 | Zoladex Subcutaneous Implant 10.8 MG, 1 Each, Unit-of-Use, Box |
|
|||
| Rx0000232 | TerSera Therapeutics LLC | 04/30/2024 | Zoladex Subcutaneous Implant 3.6 MG, 1 Each, Unit-Dose, Syringe |
|
|||
| Rx0000232 | TerSera Therapeutics LLC | 10/30/2024 | Zoladex Subcutaneous Implant 3.6 MG, 1 Each, Unit-Dose, Syringe |
|
|||
| Rx0000302 | Tetraphase Pharmaceuticals | 04/24/2024 | Xerava Intravenous Solution Reconstituted 50 MG, 1 Each, Unit-Dose, Vial Qty 12 |
|
|||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AUSTEDO 12 MG TABLET 60 |
|
|||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AUSTEDO 6 MG TABLET 60 |
|
|||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AUSTEDO 9 MG TABLET 60 |
|
|||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AZILECT 0.5MG TABLET 30 |
|
|||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AZILECT 1MG TABLET 30 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 10MG TABLET 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 12.5MG TABLET 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 15MG TABLET 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 20MG TABLET 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 30MG TABLET 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 5MG TABLET 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 7.5MG TABLET 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADIPEX-P TABLETS 37.5 MG 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADIPEX-P TABLETS 37.5 MG 30 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | AMRIX 15 MG CAPSULE ER 60 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | AMRIX 30 MG CAPSULE ER 60 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 100 MCG TABLET 28 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 200 MCG TABLET 28 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 400 MCG TABLET 28 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 600 MCG TABLET 28 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 800 MCG TABLET 28 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FIORICET 50/300/40 MG CAPSULE 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FIORICET 50/300/40/30 MG CAPSULE 100 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | GALZIN 25 MG CAPSULE 250 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | GALZIN 50 MG CAPSULE 250 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | NUVIGIL 150MG TABLET 30 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | NUVIGIL 200MG TABLET 30 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | NUVIGIL 250MG TABLET 30 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | NUVIGIL 50MG TABLET 30 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | PROGLYCEM 50MG/ML ORAL SUS 30ML |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | PROVIGIL 100MG TABLET 30 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | PROVIGIL 200MG TABLET 30 |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 10/17/2024 | SMX-TMP INJ 80MG-16MG/ML 10 X 10ML PRM |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 10/17/2024 | SMX-TMP INJ 80MG-16MG/ML 10 X 10ML PRM |
|
|||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | TRISENOX VIAL 2 MG/ML 6 ML |
|
|||
| Rx0000218 | Teva Respiratory, LLC | 04/24/2024 | QNASL PEDS Nasal Aerosol Solution 40 MCG/ACT 6.8GM |
|
|||
| Rx0000218 | Teva Respiratory, LLC | 04/24/2024 | QNASL PLV Nasal Aerosol Solution 80 MCG/ACT |
|
|||
| Rx0000219 | Teva Women's Health, Inc. | 04/24/2024 | TREXALL 10 MG TABLET 30 |
|
|||
| Rx0000219 | Teva Women's Health, Inc. | 04/24/2024 | TREXALL 15 MG TABLET 30 |
|
|||
| Rx0000219 | Teva Women's Health, Inc. | 04/24/2024 | TREXALL 5 MG TABLET 30 |
|
|||
| Rx0000219 | Teva Women's Health, Inc. | 04/24/2024 | TREXALL 7.5 MG TABLET 30 |
|
|||
| Rx0000134 | Therakos, Inc. | 04/30/2024 | UVADEX (Methoxsalen) STERILE SOLUTION, 20 mcg/ML, 12 - 10ml vials per carton |
|
Mallinckrodt believes the pricing of our products is reflective of the benefits of therapy to patients and the healthcare system. The company is committed to ensuring appropriate patients have access to therapy, and Mallinckrodt continues to invest to achieve that goal. We further note that Uvadex is a unique prescription drug product is used only as a component of extracorporeal photopheresis (ECP) therapy, a drug/device combination therapy, and is administered by a healthcare professional in a clinical setting. | ||
| Rx0000395 | Travere Therapeutics, Inc. | 10/25/2024 | Filspari Oral Tablet 200 MG 30 tablets 1 bottle |
|
Following positive long-term confirmatory results from the PROTECT Study, the largest and only head to head Phase 3 study in IgAN, FILSPARI received full FDA approval with an expanded indication to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. | ||
| Rx0000395 | Travere Therapeutics, Inc. | 10/25/2024 | Filspari Oral Tablet 400 MG 30 tablets 1 bottle |
|
Following positive long-term confirmatory results from the PROTECT Study, the largest and only head to head Phase 3 study in IgAN, FILSPARI received full FDA approval with an expanded indication to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 100MG 60 TABLETS | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 100MG UNIT DOSE CARTON OF 100 TABLETS | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 10MG 60 TABLETS | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 10MG ORAL SOLUTION-300ML | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 25MG 60 TABLETS | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 25MG UNIT DOSE CARTON OF 100 TABLETS | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 50MG 60 TABLETS | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 50MG UNIT DOSE CARTON OF 100 TABLETS | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 75MG 60 TABLETS | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT IV INJECTION FOR INTRAVENOUS USE 50mg/5mL | 481045000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS | 1474484000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES | 1474484000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES | 1474484000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | FINTEPLA 2.2MG/ML, 30ML | 217281000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | FINTEPLA 2.2MG/ML, 360ML | 217281000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA 1000MG-60 TABLETS | 142692000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA 250MG-120 TABLETS | 142692000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA 500 MG-120 TABLETS | 142692000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA 750MG-120 TABLETS | 142692000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA IV-1ML INJECTION FOR INTRAVENOUS USE 500mg5mL 10 VIALS | 142692000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA ORAL SOLUTION-100MG-473ML | 142692000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA XR (LEVETIRACETAM) 500MG-60 TABLETS | 142692000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA XR 750MG (LEVETIRACETAM)-60 TABLETS | 142692000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NAYZILAM 5 MG NASAL SPRAY-0.2ML | 101614000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 1MG/24HR-30 TRANSDERMAL SYSTEM | 101614000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 2MG/24HR-30 TRANSDERMAL SYSTEM | 101614000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 3MG/24HR-30 TRANSDERMAL SYSTEM | 101614000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 4MG/24HR-30 TRANSDERMAL SYSTEM | 101614000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 6MG/24HR-30 TRANSDERMAL SYSTEM | 101614000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 8MG/24HR-30 TRANSDERMAL SYSTEM | 101614000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 100MG UD-60 TABLETS | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 100MG-60 TABLETS | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 150MG UD-60 TABLETS | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 150MG-60 TABLETS | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 200MG UD-60 TABLETS | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 200MG-60 TABLETS | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 50MG UD-60 TABLETS | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 50MG-60 TABLETS | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT INJECTION FOR INTRAVENOUS USE 200MG/20ML 10 VIALS | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT ORAL SOLUTION 10MG-200ML | 103776000 | The price increases are not necessitated by a change or improvement in the drugs. | ||
| Rx0000262 | Ultragenyx Pharmaceuticals Inc. | 04/03/2024 | Dojolvi .96 g/mL Oral Liquid 1 Carton |
|
The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs. | There are no changes or improvements in the product. | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER .125 MG Oral Tablet 10 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER .125 MG Oral Tablet 100 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER .25 MG Oral Tablet 10 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER .25 MG Oral Tablet 100 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 1 MG Oral Tablet 10 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 1 MG Oral Tablet 100 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 2.5 MG Oral Tablet 10 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 2.5 MG Oral Tablet 100 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 5 MG Oral Tablet 100 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 5 MG Pack Oral Tablet 10 Pack |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Orenitram brand assets. | Not applicable | |
| Rx0000036 | United Therapeutics | 03/31/2024 | Unituxin Intravenous Solution 17.5 MG/5ML 1 Vial in 1 Carton |
|
United Therapeutics considers multiple factors when setting a list price, including the benefits the medicine brings to patients, healthcare systems and society, as well as ongoing research-investment costs. The price increase is due to ongoing research and development, investment in innovation, and manufacturing for the Unituxin brand assets. | Not applicable | |
| Rx0000443 | USWM, LLC | 04/10/2024 | LUCEMYRA .18mg 36 Tablet |
|
response to recent economic conditions | ||
| Rx0000443 | USWM, LLC | 04/10/2024 | LUCEMYRA .18mg 96 Tablet |
|
response to recent economic conditions | ||
| Rx0000450 | Vericel Corporation | 10/23/2024 | MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 1 BAG in 1 BOX (69866-1030-5) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-4) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-3) |
|
|||
| Rx0000450 | Vericel Corporation | 10/23/2024 | MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6) |
|
|||
| Rx0000155 | Vertical Pharmaceuticals, LLC | 04/24/2024 | Corvite 150 Oral Tablet - package size 30 |
|
Our price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute this product. | no changes | |
| Rx0000155 | Vertical Pharmaceuticals, LLC | 04/24/2024 | Corvite FE package size 30 |
|
Our price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute this product. | no changes | |
| Rx0000155 | Vertical Pharmaceuticals, LLC | 04/24/2024 | Dsuvia - sublingual sufentanil citrate tablet 30 mcg, package size 1 |
|
Our price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute this product. | no changes | |
| Rx0000155 | Vertical Pharmaceuticals, LLC | 04/24/2024 | Dsuvia - sublingual sufentanil citrate tablet 30 mcg, package size 10 |
|
Our price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute this product. | no changes | |
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/10mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/20mg 30s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/20mg 30s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/40mg 30s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/40mg 30s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/80mg 30s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/80mg 30s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/10mg 30s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/10mg 30s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/20mg 30s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/20mg 30s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/40mg 30s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/40mg 30s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/80mg 30s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/80mg 30s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 1mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 2mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 4mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 8mg 100s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 8mg 100s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura XL Tabs 4mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura XL Tabs 8mg 30s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura XL Tabs 8mg 30s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 100mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 100mg 500s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 100mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 200mg 100s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 200mg 100s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 200mg 500s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 200mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 400mg 60s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 400mg 60s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 400mg UD100-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 400mg UD100-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 50mg 60s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 50mg 60s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin ER Caps 100mg 1000s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin ER Caps 100mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin ER Caps 100mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin ER Caps 30mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin Infatabs 50mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin Infatabs 50mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin-125 Oral Suspension 125mg/5mL 237mL |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 150mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 150mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 37.5mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 37.5mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 75mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 75mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 20mg 60s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 40mg 60s-New NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 40mg 60s-Old NDC |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 60mg 60s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 80mg 60s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Injection 20mg/mL SDV 10PK |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Inspra Tabs 25mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Inspra Tabs 50mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 100mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 100mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 150mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 150mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 200mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 225mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 25mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 300mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 50mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 50mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 75mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 75mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica CR Tabs 165mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica CR Tabs 330mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica CR Tabs 82.5mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Caps 100mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Caps 300mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Caps 400mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Tabs 600mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Tabs 800mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Nitrostat Sublingual Tabs 0.3mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Nitrostat Sublingual Tabs 0.4mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Nitrostat Sublingual Tabs 0.4mg 100s (Convenience Pack) |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Nitrostat Sublingual Tabs 0.6mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 10mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 10mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 2.5mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 5mg 300s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 5mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 5mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Relpax Tabs 20mg 6s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Relpax Tabs 40mg 12s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Relpax Tabs 40mg 6s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Revatio Injection 0.8mg/mL 12.5mL |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Revatio Tabs 20mg 90s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xalatan Ophthalmic Drops 0.005% 2.5mL |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 0.25mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 0.25mg 500s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 0.5mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 0.5mg 500s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 1mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 1mg 500s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 2mg 100s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax XR Tabs 0.5mg 60s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax XR Tabs 1mg 60s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax XR Tabs 2mg 60s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax XR Tabs 3mg 60s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 100mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 100mg UD100 |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 25mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 50mg 30s |
|
|||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 50mg UD100 |
|
|||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | DOVATO TAB 50-300MG 30 Tablets per BOTTLE |
|
The price increases listed are not related to any identified or claimed change or improvement. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | JULUCA TAB 50-25MG 30 Tablets per BOTTLE |
|
The price increases listed are not related to any identified or claimed change or improvement. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | RUKOBIA TAB 600MG ER 60 Tablets per BOTTLE |
|
The price increases listed are not related to any identified or claimed change or improvement. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | TIVICAY PD TAB 5MG 60 Tablets per BOTTLE |
|
The price increases listed are not related to any identified or claimed change or improvement. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | TIVICAY TAB 50MG 30 Tablets per BOTTLE |
|
The price increases listed are not related to any identified or claimed change or improvement. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | TRIUMEQ TAB 600-50-300MG 30 Tablets per BOTTLE |
|
The price increases listed are not related to any identified or claimed change or improvement. | ||
| Rx0000223 | Woodward Pharma Services LLC | 03/31/2024 | Lovaza (omega-3-acid ethyl esters) Capsules, 1g, 120 CT |
|
|||
| Rx0000380 | Xeris Pharmaceuticals, INC. | 03/31/2024 | Keveyis Oral Tablet 50 MG, |
|
|||
| Rx0000380 | Xeris Pharmaceuticals, INC. | 03/31/2024 | Keveyis Oral Tablet 50 MG, Dichlorphenamide Tab 50 MG, 100 Each, Bottle |
|
|||
| Rx0000380 | Xeris Pharmaceuticals, INC. | 10/09/2024 | Recorlev Oral Tablet 150 MG 50 per bottle |
|
|||
| Rx0000163 | Zyla Life Sciences | 07/29/2024 | Sprix (ketorolac tromethamine) 15.75mg/1 Spray, 8 Sprays / Bottle (1 Bottle) |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| Rx0000163 | Zyla Life Sciences | 07/29/2024 | Sprix (ketorolac tromethamine) 15.75mg/1 Spray, 8 Sprays per Bottle (5 Bottles per Carton) |
|
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like Californias Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. | No Change. | |
| None | None | None | None |